[
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "The Wiryadana’s Notebook",
    "section": "",
    "text": "Preface\nIn the middle of 2023, I was so fortunate that I passed the admission for Internal Medicine residency program. I believe my knowledge has been barely enough just to start the program. To compensate my lack in memorizing and attention to detail, I build this books. I published it online but not intended to disseminate widely, at least not yet. It is only to help me doing my work.\nBy the way, this is a Quarto book. Quarto is amazing innovation from Rstudio.org that makes it possible for a lay person creating online books like this one. To learn more about Quarto books visit https://quarto.org/docs/books.\n\n\nAcknowledgements\nThis book made possible by years of clinical education given by all of my teachers."
  },
  {
    "objectID": "intro.html",
    "href": "intro.html",
    "title": "1  Introduction",
    "section": "",
    "text": "This is a book created from markdown and executable code.\nSee Knuth (1984) for additional discussion of literate programming.\n\n\n\n\nKnuth, Donald E. 1984. “Literate Programming.” Comput. J. 27 (2): 97–111. https://doi.org/10.1093/comjnl/27.2.97."
  },
  {
    "objectID": "references.html",
    "href": "references.html",
    "title": "References",
    "section": "",
    "text": "Knuth, Donald E. 1984. “Literate Programming.” Comput.\nJ. 27 (2): 97–111. https://doi.org/10.1093/comjnl/27.2.97.\n\n\nLoscalzo, J, A Fauci, D Kasper, S Hauser, D Longo, and J Jameson. 2022.\nHarrison’s Principles of Internal\nMedicine, 21e. 21st ed. McGraw Hill. https://accesspharmacy.mhmedical.com/content.aspx?bookid=3095&sectionid=259856983."
  },
  {
    "objectID": "critical_care.html#airway-and-ventilation-support",
    "href": "critical_care.html#airway-and-ventilation-support",
    "title": "8  Intensive Care Medicine",
    "section": "8.2 Airway and Ventilation Support",
    "text": "8.2 Airway and Ventilation Support"
  },
  {
    "objectID": "critical_care.html#respiration-and-hemodynamics-monitoring",
    "href": "critical_care.html#respiration-and-hemodynamics-monitoring",
    "title": "8  Intensive Care Medicine",
    "section": "8.3 Respiration and Hemodynamics Monitoring",
    "text": "8.3 Respiration and Hemodynamics Monitoring"
  },
  {
    "objectID": "critical_care.html#shock",
    "href": "critical_care.html#shock",
    "title": "8  Intensive Care Medicine",
    "section": "8.2 Shock",
    "text": "8.2 Shock\n\n8.2.1 Initial Evaluation\nshock is a multisystem end-organ hypoperfusion. The resulting hypoperfusion followed by tissue hypoxia with accompanying lactic acidosis. Clinical Indicator:\n\nReduced MAP\nTachycardia\nTachypnea\nCool Skin and Extremities\nAcute Altered mental Status\nOliguria\n\nReduced MAP could be the product of decreased cardiac output and/or systemic vascular resistance (SVR). Thus every shock patients should be evaluated for adequacy of cardiac output. Sign of diminished cardiac output includes (Cold Shock):\n\nA narrow pulse preassure (SBP - DBP), marker of stroke volume\nCool extremities and delayed capillary refill time (COLD SHOCK). Palpate proximal extremities (eg Thigh) rather than distal extremities to determine relative “coolness” as peripheral artery disease may always have cool distal extremities.\n\nContrary, there are sign of increased cardiac output (Warm Shock), that may results from decreased SVR:\n\nA widened pulse pressure (particularly reduced DBP)\nWarm extremities with bounding pulse,\nRapid capillary refill time\n\nIf reduced cardiac output found, then conduct assesment of volume status.\n\nHistory suggesting fluid loss or hemmorhage\nReduced JVP\nStraight leg raise or fluid challange\nUSG Marker: inferior vena cava collapse, left ventricular stroke volume\n\nreduced cardiac function with increased intravascular volume - S3 or S4 gallop - JVP increased - Extremity Edema - Crackles on lung auscultation - Chest Xray show cardiomegaly, widening vascular pedicle, kerley B lines, pulmonary edema. - ECG: ischemic with or withour chest pain.\nIf sign of increased cardiac output found, conduct search for cause of reduced SVR.\n\nSepsis\nLiver Failure\nSevere Pancreatitis\nAdrenal Insufficiency\nBurns\nTrauma\nAnaphylaxis\nThyrotoxicosis\nPeripheral AV shunts\n\nThe need for arterial line and CVC - if shock prolonged and doest resolve with proper fluid resuscitation and vasoactive agent.\nInitial evaluation followed with early aggresive targeted resuscitation improve survival. If initial bedside evaluation yield confounding data, objective assesment with USG/Echo needed.\n\n\n8.2.2 The need for Mechanical Ventilation\nAlways asses the ability of a patient to protect his or her airway and to maintain adequate gas exhange. Early intubation or mechanical ventilation often required for two main reasons:\n\nAcute hypoxemic respiratory failure.\n\nIt may occurs in cardiogenic shock and pulmonary edema, septic shock with pneumonia or acute respiratory distress syndrome (ARDS).\n\nVentilatory failure\n\nOften occurs as a consquence of an increased load on the respiratory system in the form of acute metabolic acidosis or decreased lung compliance.\nAlso in shock, a large percentage of CO need for respiratory muscle (10 folds), lactic acid production from inefficient respiratory muscle activity presents an additional ventilatory load. Ventilatory supports relieve work of breathing and allow redistribution of limited CO to other vital organ.\nSign of respiratory distress:\n\ninability to speak full sentences,\naccessory muscle activity\nparadoxical abdominal muscle activity\nextreme tachypnea (>40 breath/min)\n\nAfter intubation and mechanical ventilation, declines in MAP frequently seen. The reasons:\n\nImpended Venous Return from positive pressure ventilation (PPV)\nreduced endogenous catecholamine secretion once stress associated with respiratory failures abates\nActions of drugs used in endotracheal intubation.\nRight heart failure patients or preexisting pulmonary hypertension, due to increased right ventricula afterload due to PPV.\n\nMany patients may be fluid responsive.Therefore, fluid administration and vasopressor support might needed before intubation.\n\n\n\n\n\n\n\nApproach to Shock"
  },
  {
    "objectID": "hematology_oncology.html#oncological-emergency",
    "href": "hematology_oncology.html#oncological-emergency",
    "title": "2  Hematology & Medical Oncology",
    "section": "2.1 Oncological Emergency",
    "text": "2.1 Oncological Emergency"
  },
  {
    "objectID": "hematology_oncology.html#hematology",
    "href": "hematology_oncology.html#hematology",
    "title": "2  Hematology & Medical Oncology",
    "section": "2.2 Hematology",
    "text": "2.2 Hematology"
  },
  {
    "objectID": "hematology_oncology.html#medical-oncology",
    "href": "hematology_oncology.html#medical-oncology",
    "title": "2  Hematology & Medical Oncology",
    "section": "2.3 Medical Oncology",
    "text": "2.3 Medical Oncology"
  },
  {
    "objectID": "nefrology.html#nefrology",
    "href": "nefrology.html#nefrology",
    "title": "9  Nefrology & urology",
    "section": "9.1 Nefrology",
    "text": "9.1 Nefrology\n\n9.1.1 Hypertension\n\n\n9.1.2 FLuid and Electrolyte Disorders\n\nDisorders of Extracelular Volume\n\n\nDisorders of Water Metabolism\n\n\nDisorders of Potassium Metabolism\n\n\nDisorders of Calcium, Phosphate and Magnesium Metabolism\n\n\nAcid-Base Balance\n\nMetabolic Acidosis\n\n\nMetabolic Alkalosis\n\n\nRespiratory Acidosis\n\n\nRespiratory Alkalosis\n\n\nMixed Acid Base Balance\n\n\n\n\n9.1.3 Infectious Disease in Kidney\n\n\n9.1.4 Acute Kidney Injury\n\n\n9.1.5 GLomerular Disease\n\n\n9.1.6 Tubulointerstitial Disease\n\n\n9.1.7 Diabetic Kidney Disease\n\n\n9.1.8 Renovascular Disease\n\n\n9.1.9 Pregnancy and Renal Disease\n\n\n9.1.10 Congenital Disease of the Kidney\n\n\n9.1.11 Chronic Kidney Disease\n\n\n9.1.12 Dialytic Therapy\n\n\n9.1.13 Transplantation"
  },
  {
    "objectID": "nefrology.html#urology",
    "href": "nefrology.html#urology",
    "title": "9  Nefrology & urology",
    "section": "9.2 Urology",
    "text": "9.2 Urology"
  },
  {
    "objectID": "endocrine_metabolism.html#emergency",
    "href": "endocrine_metabolism.html#emergency",
    "title": "11  Endocrine & Metabolism",
    "section": "11.1 Emergency",
    "text": "11.1 Emergency\n\n11.1.1 Diabetes\n\nDiabetic ketoacidosis\n\n\nHyperosmolar-hyperglicemic Syndrome"
  },
  {
    "objectID": "endocrine_metabolism.html#non-emergency",
    "href": "endocrine_metabolism.html#non-emergency",
    "title": "11  Endocrine & Metabolism",
    "section": "11.2 Non-emergency",
    "text": "11.2 Non-emergency"
  },
  {
    "objectID": "geriatry.html#emergency",
    "href": "geriatry.html#emergency",
    "title": "13  Geriatry",
    "section": "13.1 Emergency",
    "text": "13.1 Emergency"
  },
  {
    "objectID": "geriatry.html#non-emergency",
    "href": "geriatry.html#non-emergency",
    "title": "13  Geriatry",
    "section": "13.2 Non-emergency",
    "text": "13.2 Non-emergency"
  },
  {
    "objectID": "neurology.html#coma-decreased-consciousness",
    "href": "neurology.html#coma-decreased-consciousness",
    "title": "16  neurology",
    "section": "16.1 Coma & Decreased Consciousness",
    "text": "16.1 Coma & Decreased Consciousness"
  },
  {
    "objectID": "neurology.html#pain-management",
    "href": "neurology.html#pain-management",
    "title": "16  neurology",
    "section": "16.2 Pain Management",
    "text": "16.2 Pain Management"
  },
  {
    "objectID": "radiology.html#konvensional",
    "href": "radiology.html#konvensional",
    "title": "23  Radiology",
    "section": "23.1 Konvensional",
    "text": "23.1 Konvensional"
  },
  {
    "objectID": "radiology.html#ct-scan",
    "href": "radiology.html#ct-scan",
    "title": "23  Radiology",
    "section": "23.2 CT Scan",
    "text": "23.2 CT Scan"
  },
  {
    "objectID": "radiology.html#ultrasonography",
    "href": "radiology.html#ultrasonography",
    "title": "23  Radiology",
    "section": "23.3 Ultrasonography",
    "text": "23.3 Ultrasonography\n\n23.3.1 POCUS in Emergency/Critical Care Setting\n\nBlue Protocol\n\n\nRUSH/ACES Protocol"
  },
  {
    "objectID": "radiology.html#mri",
    "href": "radiology.html#mri",
    "title": "23  Radiology",
    "section": "23.4 MRI",
    "text": "23.4 MRI"
  },
  {
    "objectID": "radiology.html#nuclear-medicine",
    "href": "radiology.html#nuclear-medicine",
    "title": "23  Radiology",
    "section": "23.5 Nuclear Medicine",
    "text": "23.5 Nuclear Medicine"
  },
  {
    "objectID": "medical_procedure.html#diagnostics",
    "href": "medical_procedure.html#diagnostics",
    "title": "32  Common Medical Procedures for Internist",
    "section": "32.1 Diagnostics",
    "text": "32.1 Diagnostics"
  },
  {
    "objectID": "medical_procedure.html#therapeutics",
    "href": "medical_procedure.html#therapeutics",
    "title": "32  Common Medical Procedures for Internist",
    "section": "32.2 Therapeutics",
    "text": "32.2 Therapeutics\n\n32.2.1 Blood Transfusion"
  },
  {
    "objectID": "critical_care.html#approach-to-critical-ill-patients",
    "href": "critical_care.html#approach-to-critical-ill-patients",
    "title": "2  Emergency & Intensive Care Medicine",
    "section": "2.1 Approach to Critical Ill Patients",
    "text": "2.1 Approach to Critical Ill Patients\n\nAssesment of illness severity\nImportant for:\n\nresource allocation\nHospital administrative policies\nasses quality of care\n\nTwo most commonly used scoring systems:\n\nSOFA (Sequential Organ Failure Assessment)\nAPACHE (Acute Physiology and Chronic Health Evaluation)\n\n\nSOFA Score\nIncludes 6 organ systems, with each graded 0 to 4 according to the degree of dysfunction. Increased score correlate with mortality and can be evaluated repeatedly (Loscalzo et al. 2022).\nA derivation, the qSOFA or quick SOFA intented to screen patients for srisk of poor outcomes from sepsis. It is not intended for sepsis diagnostic screening tool, but in it often used as such in resources poor area. qSOFA used for bedside evaluation that may identify patient with suspected infection who are at greater risk for a poor outcome outside the ICU. The score range from 0 to 3 points in each three category including blood preasure, respiratory rate and mental status. Poor outcimes predicted if there at least 2 clinical criteria: (1) respiratory rate \\(\\geq\\) 22/min, altered mental status, or systolic BP \\(\\le\\) 100 mmhg.\n\n\n\n\n\n\n\n\n\n  \n    \n      Calculation of SOFA Score\n    \n    \n    \n      System\n      \n        Score\n      \n    \n    \n      0\n      1\n      2\n      3\n      4\n    \n  \n  \n    Respiration (PaO2 / FiO2)\n>= 400\n<400\n<300\n<200 with respiratory support\n<100 with respiratory support\n    Coagulation (plt)\n>= 150\n<150\n<100\n<50\n<20\n    Liver (bilirubin, mg/dl)\n<1,2\n1,2 - 1,9\n2,0 - 5,9\n6,0 - 11,9\n>12,0\n    Cardiovascular\nMAP >= 70\nMAP < 70\nDopamin <5 or dobutamine any dose\nDopamine 5,1 - 15 or epinefrin <= 0,1 or Norepinefrin <=0,1\nDopamin >15 or epinefrin >0,1 or Norepinefrin >0,1\n    CNS (GCS)\n15\n13-14\n2023-12-10\n2023-09-06\n<6\n    Renal (Creatinin mg/dl or urine output ml/day)\n1.2\n1,2 - 1,9\n2,0 - 3,4\n3,5 - 4,9 (<500 cc)\n>5,0 (< 200 cc)\n  \n  \n  \n\n\n\n\n\n\nAPACAHE Score\nSLightly more complicated than SOFA Score. (updated later)\n\n\n\n2.1.1 Shock\n\n\n2.1.2 Initial Evaluation\nshock is a multisystem end-organ hypoperfusion. The resulting hypoperfusion followed by tissue hypoxia with accompanying lactic acidosis. Clinical Indicator:\n\nReduced MAP\nTachycardia\nTachypnea\nCool Skin and Extremities\nAcute Altered mental Status\nOliguria\n\nReduced MAP could be the product of decreased cardiac output and/or systemic vascular resistance (SVR). Thus every shock patients should be evaluated for adequacy of cardiac output. Sign of diminished cardiac output includes (Cold Shock):\n\nA narrow pulse preassure (SBP - DBP), marker of stroke volume\nCool extremities and delayed capillary refill time (COLD SHOCK). Palpate proximal extremities (eg Thigh) rather than distal extremities to determine relative “coolness” as peripheral artery disease may always have cool distal extremities.\n\nContrary, there are sign of increased cardiac output (Warm Shock), that may results from decreased SVR:\n\nA widened pulse pressure (particularly reduced DBP)\nWarm extremities with bounding pulse,\nRapid capillary refill time\n\nIf reduced cardiac output found, then conduct assesment of volume status.\n\nHistory suggesting fluid loss or hemmorhage\nReduced JVP\nStraight leg raise or fluid challange\nUSG Marker: inferior vena cava collapse, left ventricular stroke volume\n\nreduced cardiac function with increased intravascular volume - S3 or S4 gallop - JVP increased - Extremity Edema - Crackles on lung auscultation - Chest Xray show cardiomegaly, widening vascular pedicle, kerley B lines, pulmonary edema. - ECG: ischemic with or withour chest pain.\nIf sign of increased cardiac output found, conduct search for cause of reduced SVR.\n\nSepsis\nLiver Failure\nSevere Pancreatitis\nAdrenal Insufficiency\nBurns\nTrauma\nAnaphylaxis\nThyrotoxicosis\nPeripheral AV shunts\n\nThe need for arterial line and CVC - if shock prolonged and doest resolve with proper fluid resuscitation and vasoactive agent.\nInitial evaluation followed with early aggresive targeted resuscitation improve survival. If initial bedside evaluation yield confounding data, objective assesment with USG/Echo needed (look Figure 2.1).\n\nThe need for Mechanical Ventilation\nAlways asses the ability of a patient to protect his or her airway and to maintain adequate gas exhange. Early intubation or mechanical ventilation often required for two main reasons:\n\nAcute hypoxemic respiratory failure.\n\nIt may occurs in cardiogenic shock and pulmonary edema, septic shock with pneumonia or acute respiratory distress syndrome (ARDS).\n\nVentilatory failure\n\nOften occurs as a consquence of an increased load on the respiratory system in the form of acute metabolic acidosis or decreased lung compliance.\nAlso in shock, a large percentage of CO need for respiratory muscle (10 folds), lactic acid production from inefficient respiratory muscle activity presents an additional ventilatory load. Ventilatory supports relieve work of breathing and allow redistribution of limited CO to other vital organ.\nSign of respiratory distress:\n\ninability to speak full sentences,\naccessory muscle activity\nparadoxical abdominal muscle activity\nextreme tachypnea (>40 breath/min)\n\nAfter intubation and mechanical ventilation, declines in MAP frequently seen. The reasons:\n\nImpended Venous Return from positive pressure ventilation (PPV)\nreduced endogenous catecholamine secretion once stress associated with respiratory failures abates\nActions of drugs used in endotracheal intubation.\nRight heart failure patients or preexisting pulmonary hypertension, due to increased right ventricula afterload due to PPV.\n\nMany patients may be fluid responsive. Therefore, fluid administration and vasopressor support might needed before intubation.\n\n\n\n\n\n\n\n\nFigure 2.1: Approach to Shock\n\n\n\n\n\n\n2.1.3 Respiratory Failure\nRespiratory failure mechanistically on the basis of pathophysiology can be categorized onto:\n\nType 1: Acute Hypoxemic Respiratory Failure\nIt occurs due to alveolar flooding, subsquent Ventilation-perfusion (VP) mismatch and intrapulmonary shunt physiology.\nAlveolar flooding occurs due:\n\npulmonary edema, pulmonary edema further caused by:\n\nelevated pulmonary microvascular pressures (heart failure or fluid overload) or\nARDS (low pressure pulmonary edema), defined as: acute onset (\\(\\le\\) 1 week) of bilateral opacities on chest imaging that are not fully explained by cardiac failure or fluid overload and ventilation perfusion mismatch, and shunt physiology that require positive end-expiratory pressure (PEEP)\n\nlung injury\npneumonia\nalveolar hemorrhage\n\nType 1 RF occurs in sepsis, gastric aspiration, pneumonia, covid-19, near drowning, multiple blood transfusion & pancreatitis.\n\nGeneral Treatment\n\nMechanical ventilation. Mechanical ventilation with high tidal volume (12 ml/kg ideal body weight) traditionally further injured the lung due to repeated alveoli overdistention and stretching. This is called ventilator induced volutrauma and even induce ARDS in patients without ARDS initialy. many studies point toward low tidal volume (6 ml/kg ideal body weight) improve survival.\nreproduce Figure of Preassure volume relathionsip!!!\nProne positioning\nLow CVP or low PCWP or fluid conservatice approach fluid conservative management to maintain low CVP or PCWP associated with fewer days with mechanical ventilation than fluid liberal approach in patients that who have been resuscitated from shock.\n\n\n\n\nType 2 Respiratory Failure: Hypercapnic Respiratory Failure\nIt is a consequence of alveolar hypoventilation and the results from inability to eliminate CO2 effectively. The cause categorized into:\n\nimpaired CNS drive to breathe (“wont breathe”) Cause: drug overdose, brainstem injury, sleep-disordered breathing, severe hypothyroidism\nreduced strength or impaired neuromuscular function in respiratory systems (“cant breathe”) cause: impaired neuromuscular transmission (eg. myasthenia gravis, Guillain-Barre syndrome, amyotrophic lateral sclerosis) or respiratory muscle weakness (eg. myopathy, electrolye problem, fatigue)\nincreased load on respiratory system (“cant breathe”) cause:\n\nincreased resistive load eg. brochospasm\nreduced lung compliance eg. alveolar edema, atelectasis, intrinsip PEEP\nreduced chest wall compliance eg. pneumothorax, pleural effusion, abdominal distention\nincreased minute ventilation requirements eg. pulmoanry embolus with increased dead space fraction, sepsis\n\n\n\ngeneral Treatment\nPrincipal: reversing the underlying cause(s). Non-invasive ventilation (NIV) with positive pressure ventilation with tight fitting mask or nasal mask (avoidance of intubation) may stabilize these patients. It tested extensively in exacerbation of COPD. Contraindication for NIV include hemodynamic instability, inability to protect airway, respiratory arrests, significant airway secretions, significant aspiration risk.\n\n\n\nType 3 Respiratory Failure: Lung Atelectasis\nThe primary cause is lung atelectasis. It is common in perioperaticve period, this form is also called perioperative respiratory failure. Post general anesthesia, there are decrease in functional residual capacity lead to collapse of dependent lung units.\n\ngeneral treatment\ntreatment include: frequent positional changes, chest physiotherapy, upright positioning, control of incisional/or abdominal pain.\n\n\n\nType 4 Respiratory Failure: Metabolic Demands\nMost often due to hypoperfusion of respiratory muscles in patients in shock. Normally, respiratory muscle consume < 5% total cardiac outpur (CO) and oxygen delivery. Patients in shock oftern experience respiratory distress due to pulmonary edema (eg. in cardiogenic shock), lactic acidosis and anemia. In these conditions, up to 40% CO distributed to respiratory muscle.\n\nGeneral Treatment\nEndotrachea intubation & mechanical ventilation allow blood redistributed to vital organ and reverse the underlying cause.\n\n\n\nMechanical Ventilation\nmechanical ventialtion is used to assist or replace sponstaneus breathung. Its application of high oxygen content + positive pressure. Primary indication is acute respiratory failure which there are two basic types: 1. hypoxemic and 2. hypercarbic. Hypoexemic present when arterial O2 saturation <90% despite increased inspired O2 fraction due to ventilation perfusion mismatch or shunting. Hypercarbic characterized by elevated arterial CO2 (usually >50 mmHg) resulting from conditions that decrease minute ventilation or increased physiologic dead space.\n\nTypes of Mechanical Ventilation\nthere are two types of MV: noninvasive ventilation (NIV) and invasive (conventional MV)\n\nNoninvasive ventilation\nNIV: effective in acute and chronic respiratory failure with fewer complication (pneumonia & tracheolaringeal trauma). NIV provided by tight fitting mask, a nasal mask similar to taht used for sleep apnea. It is especially effective in COPD. Modes used are bilevel positive airway pressure (BiPAP) or pressure support ventilation (PSV). Both used positive pressure during inspiration and expiration, althouhg lower in expiration. Trial showed: COPD exacerbation ph 7,25 - 7,35 associated with good outcomes, for ph <7,25 the failure increase with decreasing ph. patient with ph >7,35 NIV is not better than conventional treatment (controlled O2, systemic glucocorticoid, bronchodilator and antibiotics).\nTHe used of NIV in other respiratory failure is limited, and in some conditions contraindicated (cardiac arrest, respiratory arrest, decreased consciousness, GI bleeding, hemodynamic instability, MI, facial trauma, upper airway obstruction, inability to clear secretion), and may delay life saving measure. Reduced respiratory rate, decreased the use of accesory muscle (scalene, sternomastoid and intercostal) are good clinical indicator of improvement. ABG should be evaluated hours after NIV initiation, if no improvement it may need a conventional MV\n\n\nInvasive Ventilation (Conventional MV)\nIntubation (cuffed tibed inserted to trachea) to allow conditioned (warmed, oxygenated, humidified) gas delivered to the airways.\nPrinciples of MV: optimize oxygenation while avoiding ventilator-induced lung injury due to overstretch and collapse/re-recruitment (protective ventilatory strategy)\n\n\n\nModes of Ventilation\nmodes are the manner in which breaths are triggered, cycled and limited. - trigger: inspiratory effort or time based signal - cycle : refers to the factors that determine the end of inspiration (volume, pressure and time cycling) - limiting factors are operator-specified values: airway pressure.\nMost patient ventilated with assist-control, intermittent mandatory ventilation, PSV.\n\nAssist control ventilation\nAssist control (ACMV) is the most widely used. Used in initiation of MV. trigger: initiated by patient inspiratory effort, if none detected, by specified time signal. cycle: pressure or volume cycle. limit: specified tidal-volume, RR defined by patients rate or backup rate.\nproblem: auto-peep might occurs if dynamic hyperinflation due to high RR happens.\n\n\nIntermittent Mandatory Ventilation\nMost commmon modes: SIMV trigger: set mandatory breath, between each mandatory breath patient can breath spontaneously. in SIMV, mandatory breath delivered in syncrony with patients breath.if patient fail to initiate a breath, the machine give fixed volume and reset its timer for next breath. cycle: defined volume, limit:\ndifference with ACMV: only the a preset number of breath are ventilator-assisted. SIMV allowd patients with intact respiratory drive to exercise inspiratory msucles between assisted breath, useful for supporting and weaning intubation. problem: difficult to use in tacypnea, due to expiration attemp during ventilator inspiratory cycle. The pressure increase, and may abort the inspiration and thus lower tidal volume. In contrast, for tachypnea represent of metabocl or respiratory acidosis, change in ACMV will increase minute ventilation and help normalize pH\n\n\nPressure-support Ventilation\ntrigger: patient breath cycle: flow, isnpiration is terminated when airflow fall below a certain level. limit: pressure\nprovides graded asistence and differs from the other two in that the operator set the pressure level to augment every spontaneous breath. The level of pressure is adjusted by observing the patiens RR.\n\n\nPressure-Control Ventilation (PCV)\nuseful to limit peak pressure, in patients with preexisting barotreauma or post htoracic surgery.\ntrigger: time cycle: time, limit: pressure\nminute ventilation is altered through RR and pressure control.\n\n\nContinous Positive Airway Pressure (CPAP)\nAll ventilation occurs through the patients spontaneus efforts. The machine provide fresh gas to the circuit and set constant pressure.\n\n\n\nProtective Ventilatory Strategy\nWhatever the modes of MV, the principles:\n\nSet target tidal volume close to 6 ml/kg of ideal body weight\nPrevent plateu pressure exceed 30 cm H2O\nUse the lowest possible FIO2 to keep SaO2 \\(\\ge\\) 90%\nAdjust the PEEP to maintain alveolar patency while preventing overdistention and closure/reopening.\n\n\n\nMaintenance for mechanical Ventilated patients\nRespiratory System Mechanics\nPeak airway pressure dtermined by two variable: airway resistance and respiratory system compliance. At the end of inspiration, there are transient pause of inspiratory flow, the pressure called plateu pressure. Plateu pressure determined by respiratory system compliance. During volume controlled ventilation, the difference peak airway pressure (airway + respiratory system) and plateu pressure (respiratory system) provides a quantitative assesment of airway resistance. Patients with increased airway resistence typically have increased peak airway pressures and abnormally high gradients between peak and plateu airway pressure (> 10 - 15 cmH2O) at a constant inspiratory flow rate of 1 L/s(shown in figure Figure 2.2. Normally, respiratory system compliance is ~ 100 ml/cmH2O, divided by the lungs and chest wall. Pathophysiologic process decrease wall compliance such as pleural effusion, pneumothorax & increase abdominal girth. Lung compliance decreased by pneumonia, pulmonary edema, alveolar hemorrhae, interstitial lung disease, or auto PEEP. Auto-PEEP occurs when there is insufficient time for emptying of alveoli before the next inspiratory cycle, thus alveoli failed to decompress fully and remains positive pressure at all phase of respiration. Theis phenomenon results most commonly from obstruction of distal airways such as Asthma or COPD.\n\n\n\nFigure 2.2: Graph Illustration taken from harrison\n\n\nPatients frequently require sedatives & analgetics.\n\nAnalgesics\nOpieates is the mainstay of mechanicaly ventilated patients\n\n\nSedatives\nAfter pain adequately controlled, sedation needed for anxiolysis, treatment of subjective dyspnea, reduction of autonomic hyperactiviy, reduction of total O2 consumption. Nonbenzodiazepin are preffered because benzodiazepin associated with increased delirium and worse patients outcome.\nAmnesia could be achieved with propofol or benzodiazepine such lorazepam or midazolam.\n\n\nNeuromuscular Blocking Agents\nPatients with ventilatory dyssyncrony despite optimal sedation may needed paralytics agents. Wathout for prolonged weakness, a myopathy known as the postparalytics syndrome. Thus, neuromuscular blocking is the last agent, only in patients which fail to achieve ventilator syncrony with aggresive sedation. Remember, neuromuscular blocking agent do not results in pharmacological paralysis without altering mental status, thus sedative is almost always required for amnesia.\n\n\n\nVentilator Weaning and Extubation\nRecognition of patients readyness to be liberated from mechanical ventilation is important. Screening conducted daily, criteria:\n\nStable oxygenation (Pao2 / Fio2 > 200 and PEEP \\(\\le\\) 5 cm H2O)\nCough and Airway Reflexes Intact\nNo Vasopressor administered\nNo Sedatives adminsitered\n\nif all requirement passed, patient should undergi a spontaneous breathing trial (SBT), if sedative still administered, patients could also undergo spontaneous awakening trial (SAT.\nSAT/SBT trial consist of a period of breathing through endotracheal tube with little or without ventilator support (CPAP 1-5 cmH2O with or without low-level pressure support (PSV) and open T-piece breahing system) for 30 - 120 minutes. SBT Failure or should be stopped if:\n\nRR >35 min for >5 min\nO2 saturation <90%\nHR > 140x/min or a 20% increase or decrease from baseline\nSBP <90 mmHg or >180 mmHg\nIncreased anxiety or diaphoresis\n\nif none of these events occured, patients should considered for an extubation trial. Despite these carefull criteria, 10% patients develop respiratory distress after extubation and may require resumption of mechanical ventilation and reintubation.\nOnce patients determined that able to breath spontaneously, then proceeed to remove the artificial airway which should be undertaken only when it is patients showed the ability to protect airway, able to cough and clear secretions, alert enough to follow commands. If reintubation is deemed difficult if required, evaluation with cuff-leak test is supported by evidence. If possibility of post-extubation stridor, administration of systemic steoroid should be given.\n\n\n\nProlonged MV and Tracheostomy\n5-13 % patients with MV will go on to require prolonged MV (>21 days). It is important to decide whether and when to perform a trachoestomy. Tracheostomy is though to be more comfortable, require less sedation, and provide a more secure airway and reduce weaning time.\nIn general, if a need of MV for >10-14 days, a tracheostomy would be indicated.\n\nMaintenance for mechanical Ventilated patients\nRespiratory System Mechanics\nPeak airway pressure dtermined by two variable: airway resistance and respiratory system compliance. At the end of inspiration, there are transient pause of inspiratory flow, the pressure called plateu pressure. Plateu pressure determined by respiratory system compliance. During volume controlled ventilation, the difference peak airway pressure (airway + respiratory system) and plateu pressure (respiratory system) provides a quantitative assesment of airway resistance. Patients with increased airway resistence typically have increased peak airway pressures and abnormally high gradients between peak and plateu airway pressure (> 10 - 15 cmH2O) at a constant inspiratory flow rate of 1 L/s(shown in figure Figure 2.2. Normally, respiratory system compliance is ~ 100 ml/cmH2O, divided by the lungs and chest wall. Pathophysiologic process decrease wall compliance such as pleural effusion, pneumothorax & increase abdominal girth. Lung compliance decreased by pneumonia, pulmonary edema, alveolar hemorrhae, interstitial lung disease, or auto PEEP. Auto-PEEP occurs when there is insufficient time for emptying of alveoli before the next inspiratory cycle, thus alveoli failed to decompress fully and remains positive pressure at all phase of respiration. Theis phenomenon results most commonly from obstruction of distal airways such as Asthma or COPD.\n\n\n\nGraph Illustration taken from harrison\n\n\nPatients frequently require sedatives & analgetics.\n\nAnalgesics\nOpieates is the mainstay of mechanicaly ventilated patients\n\n\nSedatives\nAfter pain adequately controlled, sedation needed for anxiolysis, treatment of subjective dyspnea, reduction of autonomic hyperactiviy, reduction of total O2 consumption. Nonbenzodiazepin are preffered because benzodiazepin associated with increased delirium and worse patients outcome.\nAmnesia could be achieved with propofol or benzodiazepine such lorazepam or midazolam.\n\n\nNeuromuscular Blocking Agents\nPatients with ventilatory dyssyncrony despite optimal sedation may needed paralytics agents. Wathout for prolonged weakness, a myopathy known as the postparalytics syndrome. Thus, neuromuscular blocking is the last agent, only in patients which fail to achieve ventilator syncrony with aggresive sedation. Remember, neuromuscular blocking agent do not results in pharmacological paralysis without altering mental status, thus sedative is almost always required for amnesia.\n\n\n\nVentilator Weaning and Extubation\nRecognition of patients readyness to be liberated from mechanical ventilation is important. Screening conducted daily, criteria:\n\nStable oxygenation (Pao2 / Fio2 > 200 and PEEP \\(\\le\\) 5 cm H2O)\nCough and Airway Reflexes Intact\nNo Vasopressor administered\nNo Sedatives adminsitered\n\nif all requirement passed, patient should undergi a spontaneous breathing trial (SBT), if sedative still administered, patients could also undergo spontaneous awakening trial (SAT.\nSAT/SBT trial consist of a period of breathing throung endotracheal tube without ventilator support (CPAP 5 cmH2O with or without low-level pressure support and open T-piece breahing system) for 30 - 120 minutes. SBT Failure or should be stopped if:\n\nRR >35 min for >5 min\nO2 saturation <90%\nHR > 140x/min or a 20% increase or decrease from baseline\nSBP <90 mmHg or >180 mmHg\nIncreased anxiety or diaphoresis\n\nif none of these events occured, patients should considered for an extubation trial. Despite these carefull criteria, 10% patients develop respiratory distress after extubation and may require resumption of mechanical ventilation and reintubation.\n\n\n\n\n2.1.4 Multiorgan system failure\nMultiorgan system failure, defined by the simultaneous presence of physiologic dysfunction and/or failure of two or more organs. Organ failure, no matter how it is defined must persist beyond 24 hours."
  },
  {
    "objectID": "critical_care.html#respiratory-failure",
    "href": "critical_care.html#respiratory-failure",
    "title": "8  Intensive Care Medicine",
    "section": "8.3 Respiratory Failure",
    "text": "8.3 Respiratory Failure\nRespiratory failure mechanistically on the basis of pathophysiology can be categorized onto:\n\n8.3.1 Type 1: Acute Hypoxemic Respiratory Failure\nIt occurs due to alveolar flooding, subsquent Ventilation-perfusion (VP) mismatch and intrapulmonary shunt physiology.\nAlveolar flooding occurs due:\n\npulmonary edema, pulmonary edema further caused by:\n\nelevated pulmonary microvascular pressures (heart failure or fluid overload) or\nARDS (low pressure pulmonary edema), defined as: acute onset (\\(\\le\\) 1 week) of bilateral opacities on chest imaging that are not fully explained by cardiac failure or fluid overload and ventilation perfusion mismatch, and shunt physiology that require positive end-expiratory pressure (PEEP)\n\nlung injury\npneumonia\nalveolar hemorrhage\n\nType 1 RF occurs in sepsis, gastric aspiration, pneumonia, covid-19, near drowning, multiple blood transfusion & pancreatitis.\n\nGeneral Treatment\n\nMechanical ventilation. Mechanical ventilation with high tidal volume (12 ml/kg ideal body weight) traditionally further injured the lung due to repeated alveoli overdistention and stretching. This is called ventilator induced volutrauma and even induce ARDS in patients without ARDS initialy. many studies point toward low tidal volume (6 ml/kg ideal body weight) improve survival.\nreproduce Figure of Preassure volume relathionsip!!!\nProne positioning\nLow CVP or low PCWP or fluid conservatice approach fluid conservative management to maintain low CVP or PCWP associated with fewer days with mechanical ventilation than fluid liberal approach in patients that who have been resuscitated from shock.\n\n\n\n\n8.3.2 Type 2 Respiratory Failure: Hypercapnic Respiratory Failure\nIt is a consequence of alveolar hypoventilation and the results from inability to eliminate CO2 effectively. The cause categorized into:\n\nimpaired CNS drive to breathe (“wont breathe”) Cause: drug overdose, brainstem injury, sleep-disordered breathing, severe hypothyroidism\nreduced strength or impaired neuromuscular function in respiratory systems (“cant breathe”) cause: impaired neuromuscular transmission (eg. myasthenia gravis, Guillain-Barre syndrome, amyotrophic lateral sclerosis) or respiratory muscle weakness (eg. myopathy, electrolye problem, fatigue)\nincreased load on respiratory system (“cant breathe”) cause:\n\nincreased resistive load eg. brochospasm\nreduced lung compliance eg. alveolar edema, atelectasis, intrinsip PEEP\nreduced chest wall compliance eg. pneumothorax, pleural effusion, abdominal distention\nincreased minute ventilation requirements eg. pulmoanry embolus with increased dead space fraction, sepsis\n\n\n\ngeneral Treatment\nPrincipal: reversing the underlying cause(s). Non-invasive ventilation (NIV) with positive pressure ventilation with tight fitting mask or nasal mask (avoidance of intubation) may stabilize these patients. It tested extensively in exacerbation of COPD. Contraindication for NIV include hemodynamic instability, inability to protect airway, respiratory arrests, significant airway secretions, significant aspiration risk.\n\n\n\n8.3.3 Type 3 Respiratory Failure: Lung Atelectasis\nThe primary cause is lung atelectasis. It is common in perioperaticve period, this form is also called perioperative respiratory failure. Post general anesthesia, there are decrease in functional residual capacity lead to collapse of dependent lung units.\n\ngeneral treatment\ntreatment include: frequent positional changes, chest physiotherapy, upright positioning, control of incisional/or abdominal pain.\n\n\n\n8.3.4 Type 4 Respiratory Failure: Metabolic Demands\nMost often due to hypoperfusion of respiratory muscles in patients in shock. Normally, respiratory muscle consume < 5% total cardiac outpur (CO) and oxygen delivery. Patients in shock oftern experience respiratory distress due to pulmonary edema (eg. in cardiogenic shock), lactic acidosis and anemia. In these conditions, up to 40% CO distributed to respiratory muscle.\n\nGeneral Treatment\nEndotrachea intubation & mechanical ventilation allow blood redistributed to vital organ and reverse the underlying cause.\n\n\n\n\nLoscalzo, J, A Fauci, D Kasper, S Hauser, D Longo, and J Jameson. 2022. Harrison’s Principles of Internal Medicine, 21e. 21st ed. McGraw Hill. https://accesspharmacy.mhmedical.com/content.aspx?bookid=3095&sectionid=259856983."
  },
  {
    "objectID": "critical_care.html#specific-critical-illness",
    "href": "critical_care.html#specific-critical-illness",
    "title": "2  Emergency & Intensive Care Medicine",
    "section": "2.2 Specific Critical illness",
    "text": "2.2 Specific Critical illness\n\n2.2.1 Acute Respiratory Distress Syndrome (ARDS)\nARDS is clinical syndrome of severe dyspnea of rapid onset, hypoxemia, and diffuse pulmonary infiltrates leading to respiratory failures.\n\n\n2.2.2 Diagnostic Criteria for ARDS\n\n\n\n\n\n\n  \n    \n    \n      Severity (PaO2/FiO2)\n      Onset\n      Chest Radiograph\n      Absence of Left Atrial Hypertension\n    \n  \n  \n    mild: 200 mmHg< X  <=300 mmHg; moderate: 100 mmHg < X <=200 mmHg; Severe: <= 100 mmHg\nAcute: within 1 week of clinical insult or new, or worsening respiratory symptoms\nBilateral opacities consistent with pulmonary edema not fully explained by effusion, lobat/lung collapse, or nodules\nHydrostatic edema is not the primary cause of Respiratory Failure\n  \n  \n  \n\n\n\n\nddx: - cardiogenic pulmonary edema - bilateral pneumonia - alveolar hemorrhage\n\n\n2.2.3 Epidemiology\nEstimated incidence: 60/100.000 population.\n\nEtiology\nARDS can be caused by diffuse lung injury from many medical and surgical disorders. It may be direct (on the lung) or indirect (extrapulmoner including thoracic structure). The most case (>80%) are caused by pneumonia and sepsis. Then, gastric aspiration, trauma, multiple transfusiion, pancreatitis, and drug overdose. Traumatic cause include pulmonary contusion, multiple bone fractures, chest trauma/flail chest. The risk increase with predisposing medical condition.\n\n\nPathophysiology\nNatural history of ARDS divided into 3 phases - exudative, proliferative, and fibrotic.\n\nExudative Phase\nThis phase encompases the first 7 days after precipitating ARDS risk factor. The alveolar capillary endhotelial cells and type 1 pneumocytes injured, loss of tight alveolar barrier to fluid and macromolecules. Edema fluid contain protein accumulates in the interstitial and alveolar spaces. Proinflamatory cytokines increase followed by leukocytes recruitment. The leaked plasma condensed and agrreagte in the air spaces + cellular debris + dysfunctional surfactant to form hyaline membran whorls.\nAlveolar edema predominantly involves dependent portions of the lung with diminished aeration. Large lung dimineshed aeration cause increase in lung compliance. Alteration in alveolar spaces are exacerbated by microvascular occlusion leading to reduced perfusion and pulmonary hypertension. it also cause intrapulmonary shunting and hypoxemia, leading to dyspnea.\nsign: - dyspnea, may leads to respiratory fatigue - chest radiograph reveals opacities resembling pulmonary edema. distinguishing featues from cardiogenic pulmonary edema are no cardiomegaly, no pleural effusin, or no pulmonary vascular redistribution. - laboratory finding indicative of the underlying disoder.\n\n\nProliferative Phase\nphase day 7 to 21. May showed an improvement, including weaning of mechanical ventilation. It may shows some degree of lung repair, reduced alveolar exudates, and shift to lymphocytes predominant infiltrat, increased surfactant.\nsign: - improvement in symtoms, but still dyspnea - tachypnea - hypoxemia\n\n\nFibrotic Phase\nPhase 3-4 weeks after lung injury. Many patients may recover, but some enter a fibrotic phase. The exudate convert to extensive alveolar duct and interstitial fibrosis. desctruction of acinar architecture leads to emphysema like changes (bullae), and may also develop microvascular occlusion and pulmonary hypertension.\n\n\n\nTreatment\n\nGeneral Principles\nEmphasize on treatment of the Critical ill\n\ntreatment of underlying cause\nminimization of unnecessary procedures\nstandardized bundle care\npromt recognition of nosocomial infections\nadequte nutrition\n\n\n\n\n\n\nFigure 2.3: ARDS Algorithm\n\n\n\n\n\nMechanical Ventilation\nPatient meeting criteria ARDS frequently become respiratory fatigues, so it requires mechanical ventilation.\n\nMinimize ventilator induced lung injury\nMechanical ventilatio (MV) can save lifes, but also can aggravate lung injury due to volutrauma and atelectrauma. Volutrauma can occurs due to overdistention of alveoli due to effort to inflate the consolited lungs thus damaging the still functioning alveoli.\n\nLow tidal volume 6ml/kg predicted body weight are better than coenventional 12 ml/kg bodyweight.\nlower airway pressure, plateu pressure \\(\\le\\) 30 cm H2O.\nRR \\(\\le\\) 35\n\n\n\nMinimize atelectrauma\nIn presence of fluid and loss of surfactant, PEEP is required to prevent atelectasis. PEEP is adjusted to minimize FIO2 while able to provide adequate PaO2 without causing alveolar overdistention. Follow table of PEEP-FiO2 combinations from ARDS Network trial.\nother technique includes recruitment manuever, that transiently increase PEEP to high levels to recruit ateletatic lung can increase oxygenation, but a mortality benefit has not been established.\n\n\nProne positioning\nIt improves survival.\n\n\n\nFluid Management\nincreased pulmonary vascular permeability leading to interstitial and alveolar edema fluid rich in protein is a centra features of ARDS. impaired vascular integrity augments the normal increase in extravascular lung water. Thus keeping low left atrial filling pressure could minimize pulmonary edema. Fluid restriction and diuretics should be an important aspect of ARDS management, limited only by hypotension and hypoperfusion.\n\n\nNeuromuscular blockage\nSedation alone may not adequate for ventilator syncrony. Selective use of neuromuscular blockage for ventilator syncrony could improves survival.\n\n\nGlucocorticoids\nCurrent evidence does not support the routine use of glucocorticoids.\n\n\n\nPrognosis\nextrapulmonary organ failures and sepsis counts > 80% of deaths. Risk factor for reduced survival are age (>60 yo), preexistin organ dysfunction. Patients who survives despite prolonged respiratory failures and dependent on MV may recover within 6 months.\n\n\n\n2.2.4 Approach to Circulatory Shock\nshock is the clinical condition of organ dysfuntion resulting from imbalance between celular oxygen supply and demand. Shock is reversible in early state, but if left untreated leads to multisystem organ dysfunction and death.\n\nPathophysiology of Shock\nThe cellular oxygen imbalance most commonly related to impaired oxygen delivery in the setting circulatory failure. - shock may also occurs in the setting of failure oxygen utilization (cyanide poisoning) - and state of increased oxygen demand.\nIn the setting of inadequate oxygen supply, the cell cannot maintain aerobic metabolism, thus forced into anaerobic metabolism and produce lactate and less ATP. Less ATP supply impaired cell ability to maintain hemeostasis such as maintaining N/K pump. Celular pump failure cause influx of calcium and leads to activation of phospolipases and protease, causing cellular swelling and death. In addition, hypoxia cause leakage of intracellular contents to the extracellular space, activating inflamatory cascasdes.\nOxygen delivery influenced by two major components, namely Cardiac Output (CO) and arterial oxygen content (CaO2.\nDO2 = CO x CaO2, major determinants of CO are HR and SV\nDO2 = (HR x SV) x CaO2, major determinants of SV are preload, afterload (SVR), and cardiac contractility. thus\nSV ~ (Preload x Contractility)/SVR\nPreload refees to myocardical fibers lenght before contraction (LV-EDV). Contractility refers to the ability of the ventricile to contract independent of preload and afterload. SVR represent afterload, force that ventricle must overcome to send the blood out of the cardiac cambers.\nThe CaO2 is composed of oxygen carried by convection with hemoglobin and oxygen dissolved in blood,\nCaO2 = (Kg x 1,39 x SaO2) + (PaO2 x 0,03)\nA disease process that affects these variables (HR, preload, contractility, SVR, SaO2, or Hb) has potential to reduce DO2.\n\n\nClassification of Shock\nFour major shock types are distributive, cardiogenic, hypovolemic, and obstrictive. Each has unique hemodynamics profile.\n\nDistributive Shock\nDistributive shock is condition of reduced O2 delivery where the primary physiologic distubance is reduction in SVR. There are increase of CO as a compensatory effort. CVP and PCWP reduced. The most common etiology is sepsis. Sepsis is life-threatening organ dysfunction due to dysregulated host response to infection. If accompanied by persistent hypotension despite adequate fluid resuscitation and needed vasopressor support, it is called septic shock. Other medical cause : Anaphylaxis (IgE mediated vasodilatation after exposure to allergen), pancreatitis, severe burns, liver failure. There almost 35% extravasation of circulating blood volume within 10 minutes. Patiens with severe brain or spinal cord injury may have a reduction in SVR due to disruption of autonomic pathways and blood pooling in venous system. Other cause is adrenal insuficiency due to chronic steroid use, medication , malignancy, adrenal hemmorhage, infection or autoimune. Acute stress condition, created deficit in steroid, and cause vasodilatation as well as aldosteron deficiency-mediated hypovolemia.\n\n\nCardiogenic Shock\nCardiogenic shock is characterized by reduced O2 delivery related to a reduction in CO owing to a primary cardiac problem. There are compensatory response as an increase in SVR. If left ventricle is dysfunction, there will be increased PCWP, and if right ventricle is will present as increased CVP. SV may reduced due to reduced contractility (MI, Cardiomyopathies, myocarditis), valvular disease, or due to alteration in HR (bradiaritmia and tachyarithmia)\n\n\nHypovolemic Shock\nHypovolemic shock encompasses disease that reduce CO and DO2 via a reduction in preload. There is elevation is SVR and low CVP-PCWP. Most common cause is hemmorhage followed by fluid loss from diarhea or vomiting, diuresis, skin damage.\n\n\nObstructive Shock\nObstructive shock is reduced O2 delivery related to reduced CO because impairment in blood flow, both inflow and outflow, in extracardiac pulmonary vascular or other mechanical process. Inflow obstruction Etiology: tension pneumothorax, cardiac tamponade, restrictive pericarditis. Outflow obstruction etiology: pulmonary embolism, venous air embolis, fat embolism or aortic dissection.\nUGD => hypovolemic (30,8%) > septic (27,2%) > distributive non septic (23,4%) > cardiogenic (14%) >>>> obstructiove shock (0,9%). ICU => Shock predominates )62%) >> Hypovolemic (16%) ~ cardiogenic shock (15%) >>> obstructive shock (2%).\nMortality rate: cardiogenic ~ septic > hypovolemic\n\n\n\nStages of Shock\nThere are 3, preshock, shock and irreversible shock. Body utilize variety of physiologic response to counter initial insult. There no overt sign of organ dysfunction. Lab: slight elevation of creatine or troponin or mild elevation of lactate. If host compensatory mechanism are not enough, organ dysfuction occurs and irreversible Shock ensued.\n\n\nEvaluation of the patient with Shock\nearly recongition is paramount important to reverse the stages of shock. Anamnesis to find the cause. Physical examination to identify circulatory failure (hypotension SBP <90 mmHG, or MAP < 65 mmHg) and sign of organ dysfunction. Check urine output. Finding: High CO shock: warm peripherals, CRT <2 S, large pulse pressure (LOW DBP). Low CO shock: delayed CRT, cool extremities, weak pulses.\nIncreased instravasular filling pressure and JVP (cardiogenic, obstrctive shock)\nShock Index : defined as the HR/SBP with normal SI 0,5 - 0,7\nLab test: - Lactate - Renal function - liver function - cardiac enzymes - CBC - Hemostatic index - UL - PP test if needed - ECG - CXR - POCUS (RUSH, ACES, SESAME protocol)\n\n\nInitial Treatment of Shock\n\nInitiate treatment for circulatory shock.\nFind venous access and invasive monitoring if needed\n\n\nVolume Resuscitation\nThe physiologic goal of volume resuscitation is to move the patient to the nonpreload-dependent portion of the Starling curve. Most patients with any of the four shock types will benefit from an increase in intra-vascular volume. suspected septic shock, a minimum of 30 mL/kg is recommended by the Surviving Sepsis Campaign. While the need for volume resuscitation is most apparent for patients with distributive or hypovolemic shock, even patients with cardiogenic shock may benefit from cautious volume replacement. In these patients, there should be a careful assessment of volume status prior to volume administration.\nVolume resuscitation will begin with crystalloid. In patients with hypovolemic shock due to ongoing hemorrhage, volume replacement with packed red blood cells is warranted. In cases of massive transfusion, platelets and fresh frozen plasma should be provided to offset the dilution of these components during volume replacement. Because hemoglobin is a key determinant of CaCO2, red cell administration may be a part of volume replacement even without hemorrhage in order to optimize oxygen delivery if hemoglobin content is <7 g/dL.\nAssessment of intravascular volume status (and the adequacy of volume resuscitation) begins with the physical examination. The passive leg raise (PLR) test can predict responsiveness to additional intravenous fluid (IVF) by providing the patient with an endogenous volume bolus. While the patient is resting in a semirecumbent position at a 45° angle, the bed is placed in Trendelenburg position such that the patient’s head becomes horizontal and the legs are extended at a 45° angle. There is then an immediate (within 1 min) assessment of changes in CO (or pulse pressure variation as a surrogate). It is important to emphasize that one does not merely look for changes in blood pressure; if the shock patient is mechanically ventilated there is the option of looking at changes in SV variation (or pulse pressure variation) during the respiratory cycle to assess volume responsiveness. A >12% SV variation suggests a volume-responsive state. This measurement requires that the patient be in a volume cycle mode of ventilation, without breath-to-breath variations in intrathoracic pressure and without arrhythmias.\nThere is also increased use of echocardiography to assist in determination of intravascular fluid status, with a variety of static and dynamic variables The most commonly used parameters to assess adequacy of volume resuscitation are inferior vena cava (IVC) diameter and IVC collapse. Alternatively, serial assessments of LV function can be performed while volume is being administered. Placement of a pulmonary artery catheter (PAC) is another tool for assessment of volume status. This more invasive measure involves placement of the PAC into the central venous circulation and through the right heart. Ports in the PAC (Swan-Ganz catheter) allow for direct measurement of CVP, pulmonary artery (PA), and PCWPs. The PCWP is used as a surrogate for LA pressure.\n\n\nVasopresor and Inotropic Support\nIf hypotension and inadequate tissue perfusion persist, then vasopressor and inotropic support should be initiated. The use of vasopressors and inotropes must be tailored to the primary physiologic disturbance.\nIn distributive shock, the aim is to increase the SVR. Norepinephrine is the first-choice vasopressor, with potent α1 and β1 adrenergic effects. The α1 causes vasoconstriction while β1 has positive inotropic and chronotropic effects. At high doses, epinephrine has a similar profile (at lower doses the β effects predominate) but is associated with tachyarrhythmia, myocardial ischemia, decreased splanchnic blood flow, pulmonary hypertension, and acidosis. In distributive shock, vasopressin deficiency may be present. Vasopressin acts on the vasopressin receptor to reverse vasodilation and redistribute flow to the splanchnic circulation. Dopamine does not have a role as a first-line agent in distributive shock.\nFor patients with cardiogenic shock, dobutamine is the first-line agent; it is a synthetic catecholamine with primarily β-mediated effects and minimal α adrenergic effects. The β1 effect is manifest in increased inotropy and the β2 effect leads to vasodilation with decreased afterload; it can be used with norepinephrine in patients with mixed distributive and cardiogenic shock.\n\n\nOxygenation and Ventilation Support\nSupplemental oxygen should be initiated and titrated to maintain SpO2 of 92–95%. patients may require intuvation and MV for two reason:\n\nprimary pulmonary process or related to LV dysfunction and elevations of PCWP. For patients with all types of shock, there can be development of ARDS and subsequent V/Q mismatch and shunt.\nhigh minute ventilatory needs to compensate for metabolic acidosis. As shock progresses, they may not be able to maintain adequate respiratory compensation.\n\nIt is important to provide ventilation with lung-protective strategies focused on low tidal volume ventilation and optimization of positive end-expiratory pressure to minimize ventilator-induced lung injury.\n\n\nAntibiotics\nFor patients presenting with undifferentiated shock, if the diagnosis of septic shock is being entertained, then broad-spectrum antibiotics should be administered after obtaining appropriate cultures. While it is ideal to initiate antibiotics after appropriate cultures, the inability to obtain cultures should not delay the start of treatment\n\n\nOther specific treatment for specific etiology\nThe initial evaluation (history, physical examination, and diagnostic testing) may have identified an etiology of shock that requires urgent lifesaving intervention in addition to the initial treatment steps out- lined above.\n\n\n\n\n2.2.5 Sepsis\n\n\n2.2.6 Cardiogenic Shock and Pulmonary edema\n\n\n2.2.7 Cardiac Arrest\n\n\n2.2.8 Neurological Critical illness"
  },
  {
    "objectID": "critical_care.html#important-calculation",
    "href": "critical_care.html#important-calculation",
    "title": "2  Emergency & Intensive Care Medicine",
    "section": "2.3 Important Calculation",
    "text": "2.3 Important Calculation\n\n2.3.1 Airway & Ventilation\n\n\n2.3.2 Circulation\n\nOxygen Delivery\nOxygen delivery (DO2 or QO2) is a function of cardiac output and the content of O2 in the arterial blood (CaO2). CaO2 is determined by HB concenctration, arterial HB saturation, and dissolved O2 disolved in plasma (not bound to HB). Equation provided at Equation 2.1. Nearly all oxygen delivered to the tissue is bound to HB. Disolved O2 are negligible.\nArterial oxygen content (CaO2) normally around 21.16 mL/dL, while the mixed venous blood (VO2) is 15.76 mL/dL, thus normal tissue extraction is around 25%. Reduced VO2 may results from inadequate CO, reduced HB or reduced SaO2. Abnormally high VO2 may be caused by fever, agitation, shivering and thyrotoxicosis.\n\\[\nQO~2~ = \\text{Cardiac Output} \\text{ (dL/min)} \\times (1.39 \\times \\text{HB concentration} \\times \\text{HB% Saturation} + 0.0031 \\times PaO2)\n\\tag{2.1}\\]\n\\[\nQO~2~ = 50 \\text{ dL/min} \\times (1.39 \\times 15 \\text{g/dL} \\times 100\\% + 0.0031 \\times 100)\n\\] \\[\nQO~2~ = 50 \\text{ dL/min} \\times 21.6 \\text{mL O2 per dL blood or CaO2} = 1058 \\text{ mL O2 per min}\n\\]\n\n\n\n\nLoscalzo, J, A Fauci, D Kasper, S Hauser, D Longo, and J Jameson. 2022. Harrison’s Principles of Internal Medicine, 21e. 21st ed. McGraw Hill. https://accesspharmacy.mhmedical.com/content.aspx?bookid=3095&sectionid=259856983."
  },
  {
    "objectID": "mkdu.html",
    "href": "mkdu.html",
    "title": "Mata Kuliah Dasar Umum",
    "section": "",
    "text": "Mata kuliah disampaikan kepada seluruh PPDS pada bulan pertama semester satu.\nMateri terdiri dari 5 bidang:\n\nFilsafat Ilmu\nBiologi Molekuler2\nStatistik Dasar\nMetode Penelitian\nEvidence-based Medicine"
  },
  {
    "objectID": "biomol.html#cell-structure-organel",
    "href": "biomol.html#cell-structure-organel",
    "title": "37  Biologi Molekular",
    "section": "37.1 Cell Structure & Organel",
    "text": "37.1 Cell Structure & Organel\nTujuan: memahami teknik teknik biologi molekuler untuk kepentingan klinis.\nSel: bagian terkecil fungsional penyusun organisme\nProkaryotic - ukuran diameter 0.2 - 2.0 mikrometer - no nuclear membrane - DNA sirkuler - etc\nEukaryotic - ukuran diameter 10 - 100 mikrometer - ada nuclear membrane - DNA dalam kromosom - etc\n\n37.1.1 Organel Sel\n\nInti Sel\n\nterdapat kromosom, mengandung DNA, protein histone dan non histone.\nCentral Dogma: DNA ditrankripsi menjadi mRNA DNA direplikasi menjadi kopi DNA lain\nmRNA akan di translasi menjadi Protein,\nJenis RNA: mRNA, tRNA, rRNA, miRNA, siRNA\n\nMembran sel\n\nTerdiri dari Fosfolipid bilayer, protein integral & perifer,\n\nSitoplasma\nRibosom subunit kecil dan besar bersatu menjadi kompleks. Ribosom bisa menmpel pada RE kasar.\nretikulum endoplasma\nmitokondria\nBadan Golgi\nLisosom\nPeroksisom"
  },
  {
    "objectID": "biomol.html#genome-organization",
    "href": "biomol.html#genome-organization",
    "title": "37  Biologi Molekular",
    "section": "37.2 Genome Organization",
    "text": "37.2 Genome Organization\nGenome => chromosome => Chromatin => Gene\nGen vs DNA\n\nGen = unit fungsional dan struktural hereditas\nDNA = Struktur template RNA\n\nUkuran panjang DNA nukleus => 3200 million base pair ukuran panjang DNA mitokondria => 16.6 kilo base pair\n\n\n\n\n\nFigure 37.1: Human Genomes\n\n\n\npol 1 mRNA pol 2 lain lain pol 3 rRna\n\n37.2.1 Protein coding genes\n\nGenes memiliki exon dan intron, ukuran bervariasi\nada genes yang tidak memilili intron => gene coding histone\ngene yang berukuran besar, pengkode dystropin, 99% menganding intron\nGen yang sering di transkripsi biasanya memiliki intron yang pendek\n\nRNA Coding Sequence DNA =>> Enhancer – Promoter ————————————————————— terminator\ntranskripsi\npre-RNA =>> 5’cap – leader – exon-intron-exon-intron-exon-intron-exon-intron—trailer— poly A tail 3’ cap dan poly A tail ditambah post transkripsi\nmature mRNA 5’cap – leader – exon—trailer— poly A tail 3’\ntranslasi di sitoplasma\nmRNA => monosistronik = 1 untai RNA menyandi 1 gen => manusia, polisistronik di prokaryotic\n\n\n37.2.2 Codon\n1 kodon terdiri dari 3 basa. terdapat 64 kodon, termasuk 3 stop kodon Lihat tabel kodon"
  },
  {
    "objectID": "biomol.html#dna-rna-structure",
    "href": "biomol.html#dna-rna-structure",
    "title": "37  Biologi Molekular",
    "section": "37.3 DNA & RNA Structure",
    "text": "37.3 DNA & RNA Structure\nCentral dogma………"
  },
  {
    "objectID": "biomol.html#signal-transduction",
    "href": "biomol.html#signal-transduction",
    "title": "37  Biologi Molekular",
    "section": "37.4 Signal Transduction",
    "text": "37.4 Signal Transduction\nKomponen membran Sel:\n\nPhospolipid bilayer bersifat amphiphatic yaitu ada sisi hidrofobik dan sisi hidrofilik. Komponen terdiri dari\n\nPhospate Head\nGlycerol Backbone\nFatty Acid Tails\n\nProtein:\n\nIntegral protein, melewati 2 lapir membran\nPeripheral protein, menempel hanya pada 1 lapis membran\n\n\nSifat fosfolipid semipermeable, yakni permeable terhadap zat selektif. - Small non polar, mudah melewati membran (Co2, O2) - Small polar, bisa melewati membran tapi lambat (ethanol) - Large Non-polar - Large Polar - Charged\nKomponen sel signalling\n\nSignal\nReseptor Sensing the signal. Terjadi perubahan struktur reseptor saat berinteraksi dgn signal\n\n2 tipe reseptor\n\nIntraseluler/cytosolic receptor eg. steorid hormone\nekstraseluler/transmembrance/cell surface membrane receptor eg. polypetide hormone (insulin, glukagon).\nTipe transmemberane reseptor:\n\nIon channel linked receptor\nG Protein Linked Receptor, aktivasi protein meningkatkan konsentrasi second messenger, terjadi proses amplifikasi signal.\nEnzyme Linked Receptor, signal mengaktivasi aktivitas enzim yang juga menjadi reseptor. contoh : tyrosine kinase, phospolipase C memotong PIP2 menjadi IP3 dan DAG\n\n\n\n\nto continued….."
  },
  {
    "objectID": "biomol.html#cell-cycle",
    "href": "biomol.html#cell-cycle",
    "title": "37  Biologi Molekular",
    "section": "37.5 Cell Cycle",
    "text": "37.5 Cell Cycle\nSiklus sel terdiri dari 2 tahap besar yaitu replikasi DNA dan segregasi sel. Siklus sell terdiri dari 4 fase: G1, S, G2 dan M. Proses siklus sel bukan hanya pembelahan, tetapi juga terkait dengan pertumbuhan sel dan proses lainnya.\nProses melibatkan poerubahan chromatin dari closed conformation (heterochromatin) yang sulit mengalami transkripsi (represed) menjadi Euchromatin (open chromatin) atau mudah transkripsi (activation)\nTerdapat beberapa checkpoint siklus sel. checkpoints ukuran sel (protein dll, massa ribosomal), DNA damage. DNA damage bisa akibat:\n\nfaktor intrinsik\nfaktor extrinsik\nKontrol dari protein: p53 chk1\n\nFaktor lain berpengaruh terhadap siklus sel - mutasi faktor checkpoint - epigenetic - aktivitas histon - smallDNA atau smallRNA, panjang 10-25 nucleotida, berfungsi mengenali transkrip untuk memotong mRNA yang sesuai.\n\n\n\n\n\n\n\n37.5.1 G1\nFase Gap 1, menentukan apakah pasien akan masuk ke tahap pembelahan. Jika ada kondisi yang tidak optimal, maka sel tidak akan masuk ke pembelahan. Durasi paling panjang ada pada G1 (12-15 hrs)\nAda peran dari fosforilasi protein retinoblastoma (RB) oleh protein CDKs (cyclin dependent kinases.\nCyclin berikatan dengan CDKS, mengaktifkan CDK, CDK lalu melakukan fosforilasi enzim enzim terkait. CDK adalah kelompok serine/theronine protein kinases.\nCDK 4/6 dan cyclin D dari unphosphorylated pRB menjadi hypofosforilasi pRb, oleh CDK4/6-cyclinD CDK 2 - cyclin E (post Repclication point)\nPerain penting protein p53 dan Mdm2 pada G1. P53 penting juga pada fase G2 jika ada yang terlewat pada fase G1. p53 berfungsi posttranslational medification, termasuk fosforilasi.\n\n\n37.5.2 S\ndurasi 6-8 jam\nCDK 2 dan cyclin A dari hypo menjadi hyperforilasi pRb, oleh CDK2-cyclinA\n\n\n37.5.3 G2\nDurasi 3-5 jam\nCDC2 - cyclin A hyperforilasi pRb\n\n\n37.5.4 M\nDurasi 1 jam CDC2 - cyclin B hyperforilasi pRb\npost M, defosforilasi pRB"
  },
  {
    "objectID": "biomol.html#free-radical-antioksidan",
    "href": "biomol.html#free-radical-antioksidan",
    "title": "37  Biologi Molekular",
    "section": "37.6 Free Radical & Antioksidan",
    "text": "37.6 Free Radical & Antioksidan"
  },
  {
    "objectID": "biomol.html#replication",
    "href": "biomol.html#replication",
    "title": "37  Biologi Molekular",
    "section": "37.7 Replication",
    "text": "37.7 Replication"
  },
  {
    "objectID": "biomol.html#mutation-dna-repair",
    "href": "biomol.html#mutation-dna-repair",
    "title": "37  Biologi Molekular",
    "section": "37.8 Mutation & DNA Repair",
    "text": "37.8 Mutation & DNA Repair"
  },
  {
    "objectID": "biomol.html#gene-expression",
    "href": "biomol.html#gene-expression",
    "title": "37  Biologi Molekular",
    "section": "37.9 Gene Expression",
    "text": "37.9 Gene Expression\nJumlah gene sel manusia ada sekitar 20 rb - 30 rb. Setiap sel somatik sama jumlahnya, yang berbeda adalah aktivasinya pada masing-masing tipe sel.\nProses transkripsi: ada inisiasi, elongasi dan terminasi. Proses translasi: iniasi, elongasi, terminasi\n\n37.9.1 Transkripsi\n\nInisiasi\nRNA Pol 1, RNA pol 2, RNA pol 3.\nPromoter mengenali sekuens DNA spesifik yang disebut responsive element dalam proses inisiasi transkripsi. Ada komples TATAA Box. Kompleks promotor menarik aparatus faktor faktor yang membentu proses transkripsi. Selain promotor adalah enhancer. Enhancer terletak lebih jauh dari gene terkait, baik upstream atau downstream yang membentuk sebuah DNA loop berikatan dengan kompleks inisiasi.\n\n\nElongasi\n\n\nTerminasi\nTerminasi terjadi karena pemotongan strand RNA pada sekuens tertentu. RNA kemudian ditambah poly A tail untuk meningkatkan stabilitas. Makin panjang Poly A tail, makin stabil.\n\n\nPost transcriptional Step in Gene Expression.\n\nmature RNA megalami splicing\nPenambahan 5’ end cap, menjadi 7 mentilguanosin cap\nPenambahan 3’ poli adenin tail\n\nTerjadi regulasi paska transkripsi melibatkan small/micro RNA.\n\n\n\n37.9.2 Translasi\n\n\n37.9.3 Regulasi Transkripsi\nRegulasi mRNA tergantung 1. kestabilan mRNA 2. pasangan mirna (RNAi) 3. keadaan sel 4. Metilasi DNA (pada sitosin)\nTranscription control of genes transcriptional regulation occurs at two interconnected levels - Histon complex - histon COde -"
  },
  {
    "objectID": "biomol.html#control-of-gene-expression",
    "href": "biomol.html#control-of-gene-expression",
    "title": "37  Biologi Molekular",
    "section": "37.10 Control of Gene Expression",
    "text": "37.10 Control of Gene Expression"
  },
  {
    "objectID": "biomol.html#genetic-variation",
    "href": "biomol.html#genetic-variation",
    "title": "37  Biologi Molekular",
    "section": "37.11 Genetic Variation",
    "text": "37.11 Genetic Variation\nMicroevolution is a change in allele frequencies in a population over generations. Three mechanism:\n\nNatural Selection\nGenetic Drift\nGene flow\n\nonly natural selection causes adaptive evolution. Hardy - Winberg Equilibrium: genetic variation will remain constant from one generation to the next in the absence of disturbing factors."
  },
  {
    "objectID": "biomol.html#genotyping",
    "href": "biomol.html#genotyping",
    "title": "37  Biologi Molekular",
    "section": "37.12 Genotyping",
    "text": "37.12 Genotyping\nProcess determining the genetic constitution of an individual and comparing to the other individual or reference sequence. Perbedaan interspesies <1%.\nGenotyping pada manusia untuk mengetahui susceptibilitas atas penyakit dan response terhadap pengobatan.\n\n37.12.1 Polimorfisme vs Mutasi\nPerubahan basa DNA, mutasi perubahan sekuens dari normal. Polimorfisme adalah perubahan basa yang merupakan variasi normal. Cut-off point antara mutasi dan polimorfisme adalah 1%, artinya variasi alele setidaknya memiliki frekuensi minimal 1% di populasi.\nPolimorfisme bisa berupa silent point mutation.\n\nSNP\nVariation when a single nucleotide in genome is altered. SNP do not always affect the way protein functions.\n\nLinked SNP/Indicative SNP : do not reside within genes, do not affect protein function, but correspond to certain characteristics\nCausative SNP: affect the way protein functions, whether:\n\nCoding SNP: located in coding region, changes the amino acid sequence\nNon-coding SNP: within gene regulatory sequences: change timing and expression of gene."
  },
  {
    "objectID": "biomol.html#stem-cell",
    "href": "biomol.html#stem-cell",
    "title": "37  Biologi Molekular",
    "section": "37.13 Stem Cell",
    "text": "37.13 Stem Cell\nSel yang belum terspesialisasi.\n\nEbroyonic Stem Cells ( inner cells mass)"
  },
  {
    "objectID": "biomol.html#molecular-biology-technique",
    "href": "biomol.html#molecular-biology-technique",
    "title": "37  Biologi Molekular",
    "section": "37.14 Molecular Biology Technique",
    "text": "37.14 Molecular Biology Technique\nDNA universal"
  },
  {
    "objectID": "biomol.html#aplication-of-molecular-biology-in-medicine",
    "href": "biomol.html#aplication-of-molecular-biology-in-medicine",
    "title": "37  Biologi Molekular",
    "section": "37.15 Aplication of Molecular Biology in Medicine",
    "text": "37.15 Aplication of Molecular Biology in Medicine"
  },
  {
    "objectID": "statistik.html#dasar-dasar-penulisan-ilmiah-kedokteran-dan-plagiarisma",
    "href": "statistik.html#dasar-dasar-penulisan-ilmiah-kedokteran-dan-plagiarisma",
    "title": "40  Statistik Kedokteran Dasar",
    "section": "40.1 Dasar-dasar Penulisan Ilmiah Kedokteran dan Plagiarisma",
    "text": "40.1 Dasar-dasar Penulisan Ilmiah Kedokteran dan Plagiarisma"
  },
  {
    "objectID": "statistik.html#kiat-kiat-publikasi-majalah-terakreditasi-dengan-ojs",
    "href": "statistik.html#kiat-kiat-publikasi-majalah-terakreditasi-dengan-ojs",
    "title": "40  Statistik Kedokteran Dasar",
    "section": "40.2 Kiat-kiat Publikasi Majalah Terakreditasi dengan OJS",
    "text": "40.2 Kiat-kiat Publikasi Majalah Terakreditasi dengan OJS\n\n40.2.1 Kendala Publikasi di Indonesia:\n\nIndonesia lack of language access. Why we dont make one in Bahasa Indonesia?\nLack of Cultural backgroud dalam menulis.\n\n\n\n40.2.2 Kenapa publikasi penting?\n\nRekognisi atas hasil penelitian anda baik pengakuan regional, nasional dan internasional\nH Index\nJaminan kolaborasi di tingkat regional, nasional, dan internasional\n\n\n\n40.2.3 Jurnal\nJurnal biasanya di rangking berdasarkan dimana jurnal tersebut di indeksasi (misal scopus, medline, ISI, Sinta, dll)\n\nKriteria Jurnal International\n\nTulisan memenuhi kaidah ilmiah dan etika keilmuan\nMemiliki ISSN\nDitulis dengan bahasa resmi PBB (inggris, france, arab, rusia, and china)\nMemiliki terbitas versi online\nDikelola secara profesional\nEditorial board pakar di bidangnya, dan berasal dari berbagai negara\nartikel ilmiah diterbitkan dalam satu isu berasal dari penulis berbagai negara\nmemuat karya ilmiah dari penulis yang berasal dari berbagai negara dalam setiap penerbitannya\nTerindeks database international berputasi.\n\nPublikasi:\n\nSubmit ke jurnal dgn OJS\nJika ditolak, edit ulang dan perbaiki.\n\nPerlu diketahui: - Penulisan naskah/manuskrip ilmiah merupakan suatu tangtangan, seni dan kemampuan mengelaborasi hasil penelitian. - Ikuti kaidah IMRAD. Introduction biasanya sudah menggambarkan M,R,D nya.\nAuthor vs Behavior\n\nAuthor\n\nWant to publish more, write in detail\npeer review essential\nother journal functions crucial\nwider dissemination\n\nReader\n\nwant to read less. (judul yg baik)\nWant integrated system\nBrowsing is crucial\nQuality information is important\nWant to read less\n\n\nUnsur Utama dalam Publikasi:\n\nIsue Etik + pernyataan tidak ada conflict of interest + Pencantuman sumber dana + Image manipulation guidelines\nGaya Selingkung dan Bahasa\n\nSesuai author guidelines\n\nStruktur naskah/manuskrip ilmiah\n\nTitle: judul clear, precise, including keywords. do not use abbreviations and jargon\nAuthors Listing: only include those who have made an intelectual contribution to the research, or those who will publicly defend the data and conclusion, and who have approved the final version. Gift (atasan, dekan, kepala lab), Guest (pemberi dana), and Ghost author (ini tidak boleh, atas dasar sembarangan mengikutkan namanya).Ghost writer, penulis lain yg menawarkan jasa (secara etika diijinkan).\nAbstract: ditulis selesai IMRAD. Tidak boleh sebelum lengkap dan menyeluruh menulis IMRAD. Bisa terjadi inkonsistensi dgn discussion.\nIntroduction: clearly state the problem being investigated, background that explains the problem, reasons for conducting the research. Summarize relevant research to provide context. State how your work differs from published work. Identify the questions you are answering.\nMethods: Jika RCT sebaiknya diregister, agar SOP penelitian bisa dibaca orang lain dan terrekognisi. PRovide the readers enough details so they can understand and replicate your research. Explain how you studied the problemm identify procedures, order the chronologically where possible. Include the frequency of observations, what types of data were recorded.\nResults: present the finding objectively, follow logical sequence, show figures/table and provide brief description.\nDiscussion: Describe your results in the context of what was already known, how the result relate, do not extend your conlusion beyond what is directly supoorted by you results, outline the next step of the study.\nReferences: acknowledge sources, citation follow journal guideline.\n\nSubmit artikel/pemilihan jurnal\nproses publikasi/peer review\n\nDulu hierarki tertinggi evidence adalah: Validitas Pada Penelitian Randomized, controlled, clinical trial.\nValiditas Internal\n\nAda kontrol\nAda Randomisasi\n\nValiditas External\n\nloss to follow up < 20%?\n\nSaat ini sudah bergeser pada Systematic Review dan Metanalysis."
  },
  {
    "objectID": "statistik.html#effect-size-confidence-interval",
    "href": "statistik.html#effect-size-confidence-interval",
    "title": "40  Statistik Kedokteran Dasar",
    "section": "40.3 Effect Size, COnfidence Interval",
    "text": "40.3 Effect Size, COnfidence Interval"
  },
  {
    "objectID": "statistik.html#uji-hipotesis",
    "href": "statistik.html#uji-hipotesis",
    "title": "40  Statistik Kedokteran Dasar",
    "section": "40.4 Uji Hipotesis",
    "text": "40.4 Uji Hipotesis\nMengacu pada distribusi populasi:\nAsumsi dasar H0; u1 = u2 (hipotesis nol,tidak ada perbedaan) H1: u1 =/ u2 (hipotesis alternatif, ada perbedaan)\nH1 diterima bila terjadi kesalahan kecil: kesalahan tipe 1, false positivie : dihitung peluang kesalahan akibat variasi sampel => nilai P batas penolakan (alpha) 0,05;0,01\n\nbeta: kesalahan tipe 2, false negative: ditetapkan\nmetafor: seperti persidangan\n\nJenis Hipotesis: - superiority testing: A lebih baik daripada B - non-inferirority: membuktukan perbedaan dalam rentang yang tak berbeda. (contoh penelitian obat biosimilar)\nmakna p value - chance play a role in sample value if H0 accepted\nsignificant level (alpha) if p< 0.05 or 0.01 as cut off dicari: power(1-beta) di set di awal 80% atau 90% ditentukan the answer yes or no tetapi tidak bisa melihat seberapa…. sehingga saat ini tidak hanya boleh melihat P value, karena harus melihat effect size dengan confidence interval.\nmenghitung confifdence interval :\n\n40.4.1 Clinician and Statistician\nNilai P tidak memberikan informasi besar perbedaan hasil (effect size) beda yang kecil saja memberikan signifikansi statsitik bila N besar\nbeda yang besar bisa tidak memberikan signifikansi statistik bila N kecil (error type 2)\nMaka perlu ukuran sampel yang sesuai, dan perlu memaknai sebuah statistical significance dengan makna klinis (clinical importance)"
  },
  {
    "objectID": "statistik.html#korelasi",
    "href": "statistik.html#korelasi",
    "title": "40  Statistik Kedokteran Dasar",
    "section": "40.5 Korelasi",
    "text": "40.5 Korelasi"
  },
  {
    "objectID": "statistik.html#regresi-sederhana",
    "href": "statistik.html#regresi-sederhana",
    "title": "40  Statistik Kedokteran Dasar",
    "section": "40.6 Regresi Sederhana",
    "text": "40.6 Regresi Sederhana"
  },
  {
    "objectID": "statistik.html#regresi-berganda",
    "href": "statistik.html#regresi-berganda",
    "title": "40  Statistik Kedokteran Dasar",
    "section": "40.7 Regresi Berganda",
    "text": "40.7 Regresi Berganda"
  },
  {
    "objectID": "statistik.html#distribusi-normal",
    "href": "statistik.html#distribusi-normal",
    "title": "40  Statistik Kedokteran Dasar",
    "section": "40.7 Distribusi normal",
    "text": "40.7 Distribusi normal\nTwo problems: Important differences are often obscured and overgeneralize.\nGeneralisisasi: - Sampel cukup dan representatif. - Random sampling. - Ada pembanding.\nCara membuat distribusi normal: 1. di log 2. di akar kuadratkan 3. Dibagi akar kuadratkan\nJika tetap tidak berdistribusi normal, lanjutkan dengan analisis non-parametrik. Non-parametrik bukan berarti tidak bisa dianalisis. Tetap bermakna.\nNormal distribution: bell shaped, symetrical distribution with mean, median and mode all coincidence at its peak.\n\n\n\n\n\nInsert Zscore Formula:"
  },
  {
    "objectID": "statistik.html#uji-t-berpasangan-dan-tak-berpasangan",
    "href": "statistik.html#uji-t-berpasangan-dan-tak-berpasangan",
    "title": "40  Statistik Kedokteran Dasar",
    "section": "40.8 Uji T berpasangan dan tak berpasangan",
    "text": "40.8 Uji T berpasangan dan tak berpasangan"
  },
  {
    "objectID": "statistik.html#one-way-anova",
    "href": "statistik.html#one-way-anova",
    "title": "40  Statistik Kedokteran Dasar",
    "section": "40.9 One Way ANOVA",
    "text": "40.9 One Way ANOVA"
  },
  {
    "objectID": "statistik.html#ancova-dan-repeated-measurements-anova",
    "href": "statistik.html#ancova-dan-repeated-measurements-anova",
    "title": "40  Statistik Kedokteran Dasar",
    "section": "40.10 Ancova dan Repeated Measurements ANOVA",
    "text": "40.10 Ancova dan Repeated Measurements ANOVA\nVariabel Y = Kuantitatif Variabel X = Kuantitaif/Kualitatif\nJika prediktornya adalah kontinous dan categorical variable, dan response variabel kontinous, maka menggunakan ANCOVA.\nAsumsi: 1. distribusi normal 2. Tidak ada outliers 3. Variansi homogen, 4. Linearity antar DV dan RV 5. Independece of errors. 6. Absence of multicolinearity 7."
  },
  {
    "objectID": "statistik.html#tabel-2-x-2-odd-ratio-prevalence-ratio-dan-relative-risk",
    "href": "statistik.html#tabel-2-x-2-odd-ratio-prevalence-ratio-dan-relative-risk",
    "title": "40  Statistik Kedokteran Dasar",
    "section": "40.11 Tabel 2 x 2, Odd ratio, Prevalence Ratio dan Relative Risk",
    "text": "40.11 Tabel 2 x 2, Odd ratio, Prevalence Ratio dan Relative Risk"
  },
  {
    "objectID": "statistik.html#prinsip-analisis-data-biner",
    "href": "statistik.html#prinsip-analisis-data-biner",
    "title": "40  Statistik Kedokteran Dasar",
    "section": "40.12 Prinsip Analisis Data Biner",
    "text": "40.12 Prinsip Analisis Data Biner"
  },
  {
    "objectID": "statistik.html#regresi-logistik-sederhana",
    "href": "statistik.html#regresi-logistik-sederhana",
    "title": "40  Statistik Kedokteran Dasar",
    "section": "40.13 Regresi Logistik Sederhana",
    "text": "40.13 Regresi Logistik Sederhana"
  },
  {
    "objectID": "statistik.html#regresi-logistik-berganda",
    "href": "statistik.html#regresi-logistik-berganda",
    "title": "40  Statistik Kedokteran Dasar",
    "section": "40.14 Regresi Logistik Berganda",
    "text": "40.14 Regresi Logistik Berganda"
  },
  {
    "objectID": "metpen.html#overview-of-clinical-research",
    "href": "metpen.html#overview-of-clinical-research",
    "title": "38  Metodologi Penelitian",
    "section": "38.1 Overview of Clinical Research",
    "text": "38.1 Overview of Clinical Research\nclinical research is medical research taht involves people, to learn more about disease and improve health care for people in the future.\ninclude: epidemiology, behavioral, health services, clinical trials.\nclinical research, not just clinical trial, it is any research design that studies humans or any materials taken from humans. it may even include animal studies that the results apply to humans.\ntype of clinical research:\n\nobservational studies => studies that aim to identify and analylyze patterin medical data.\nclinical trials/interventional studies\n\nResearch Question: FINER - Feasible - interesting - novel - ethical - relevant"
  },
  {
    "objectID": "metpen.html#association-causation",
    "href": "metpen.html#association-causation",
    "title": "38  Metodologi Penelitian",
    "section": "38.2 Association & Causation",
    "text": "38.2 Association & Causation\nSebuah hubungan belum tentu menunjukan sebab-akibat. Banyak peneliti menghindari dgmatic statement: “cause” or “produces”\nCausation: occurs when a change in one variable produces a change in another variable\n\nContributory Cause, no single specific cause of a disease. Most of disease cause by multifactorial etiologies. A risk factor may a contributory cause.\n\nThree criteria: 1. Association may be reflected by effect size 2. Prior Association, does the cause (independent var) precede the effects (dependent var) (case control or cohort), 3. Altering the cause alters the effects\nSome other features of contributory causation:\n\nConsistency: the results of study (effect size) should be consistent regardless the design, the population used.\nDose response relathionsip\nBiologic Plausibility: should make biologic sense.\nExperimental confirmation: phenomenon found in lcinical studies have to be consistent with studies in animal models.\n\n\nNecessary cause, dibuktikan sebagai satu satunya penyebab. Sebagai contoh: fullfiled by Koch’s Postulates: the organism is always found with the disease.\n\nAssociation: can be observed between many variable, but causaton only be determined from data collected from a controlled experiment.\n\nSpurious association, association no actually present in population 3 mekanisme spurious causation\n\nChance, due to random error and sampling variation (Individual chance to be a sample not equal), karakteristik sampel terlalu heterogen. Minimize random error: adequate sample size and low type 1 and type 2 error. Effect of random error can be judged from the width of the 95% confidence interval and the consistency of the results with previous evidence.\nDesign, conduct of the study, and analyze of the results,\n\nselection bias, pemilihan sampel yg tidak sesuai => randomized and blind intervention\nperformance bias, pemberian intervensi tidak setara antar sampel => randomized and blind intervention\nDetection bias, deteksi efek atau cause tidak sama => randomized and blind intervention\nTransfer bias, loss to follow up\n\nConfounding, occurs when factors which related to both independent and dependent variables. Contoh Kopi menyebabkan AMI, tetapi ada faktor merokok dimana orang ngopi juga suka merokok. Ternyata merokok yang berhubungan dgn AMI, tetapi merokok tidak berhubungan dengan AMI. Kontrol dengan by design atau by analysis.\n\nReal Association, true biological phenomena. However not due to a cause effect relationship\n\nCritical Appraisal about Harm/Etiology/Causation. follow checklist.\nPR: 1 jenis penelitian causation atau association yang menjadi ide kalian nanti penelitian."
  },
  {
    "objectID": "metpen.html#research-measurement",
    "href": "metpen.html#research-measurement",
    "title": "38  Metodologi Penelitian",
    "section": "38.3 Research Measurement",
    "text": "38.3 Research Measurement"
  },
  {
    "objectID": "metpen.html#variables-and-relathionship-between-variables",
    "href": "metpen.html#variables-and-relathionship-between-variables",
    "title": "38  Metodologi Penelitian",
    "section": "38.4 Variables and Relathionship Between Variables",
    "text": "38.4 Variables and Relathionship Between Variables\nVariable: independent, dependent, confounding variables\nother variable: mediator, moderator, external, random\nrelathioships among variables\n\nchances\nbias\nconfounding\ncausal"
  },
  {
    "objectID": "metpen.html#hypothesis-and-hypothesis-testing",
    "href": "metpen.html#hypothesis-and-hypothesis-testing",
    "title": "38  Metodologi Penelitian",
    "section": "38.5 Hypothesis and Hypothesis Testing",
    "text": "38.5 Hypothesis and Hypothesis Testing\nHypothesis:\na statement about relathionsip between two or more variables that suggest an answer to the research question, is declarative statement that predicts an expected outcome.\nResearch hypothesis: kalimat deklaratif yang mencoba memberikan jawaban sementara atas pertanyaan penelitian.\nStatistical hypotesis: biasanya tidak ditulis di proposal.\nResearch hypothesis nanti akan di uji apakah hypotesis didukukng oleh data data.\nJika hypotesis yang kita uji tidak sesuai dengan data, maka bukan berarti ilmu itu salah"
  },
  {
    "objectID": "metpen.html#sample-size-and-power",
    "href": "metpen.html#sample-size-and-power",
    "title": "38  Metodologi Penelitian",
    "section": "38.6 Sample Size and Power",
    "text": "38.6 Sample Size and Power\nSample size pentingnya untuk bisa mewakili populasi dan dapat inferensi ke populasi itu kembali, serta:\n\nuntuk mendeteksi treatment effects jika memang ada di populasi (mendapatkan hasil statistik signifikan dan secara klinis penting)\nPresisi estimasi\navoid wasting resources\navoid misleading conclusion\n\nTwo many subject proves everything, too few subject proves nothing\nKapan ketika perhitungan sample size tidak diperlukan? - Penelitian kualitatif - Pilot studi, biasanya 10 -20 subjek untuk menentukan sample size studi yang lebih besar.\nSampel size sesuai dengan design, analysis plan dan outcome. Sample size harus sesuai untuk memenuhi statistical significance dan clinically important, tanpa membuang sumber daya terlalu banyak.\nSampel size berhubungan power. Power = makin kuat penelitian mampu mendeteksi sebuah efek di populasi, maka semakin banyak sample size dibutuhkan.\nDefinition of Power: the probability of concluding the new treatment is effective if it truly is effective. Biasanya 80% type I error = the probability of concluding that the new treatment is effective if it truly is not effective. (positive palsu, alpha) type II error = the probability of concluding the new treatment not effective if it is truly effective (negative palsu, 1 - power atau beta)\nElemen menentukan sample size: \\(\\Delta\\) = effect size or difference under null hypotesis (perbedaan klinis yang dianggap penting) diambil dari studi sebelumnya dan tinjauan pustaka. Jika effect size besar, maka sampel di butuhkan lebih kecil, begitu kebalikannya \\(\\alpha\\) = type I error, 0,05 \\(\\beta\\) = type 2 error, 0,2 \\(\\sigma\\) = standard deviation, makin heterogen populasi maka sample size makin besar. r = ratio of number of patients in the two groups, usually r = 1\nHubungan sampel size dengan hasil presisi, dimana hasil confidence interval akan lebih sempit (lebih presisi) jika sample size besar. Jika hipotesis 2 arah, sample lebih besar, biasanya lebih disarankan hipotesis 2 arah. Pertimbangan tambahan sampel jika kemungkinan loss to follow up terutama pada kohort prospektif dan clinical trial. Jika cross sectional, tidak perlu. Jika tidak ada studi sebelumnya sebagai patokan sampel, maka tetap harus memperhitungkan sampel dengan cara pilot study.\nJika tidak bisa memenuhi jumlah sampel sesuai perhitungan sebelum penelitian (apriori), kita bisa mennetukan apakah hasil studi kita underpower dengan memperhitungkan hasil tes post-hoc.\nStategi meminimalkan sample size - pakai varibael kontinyu - paired measurement.\nrule of thumb: 10 - 50 per variabel, atau 30 sampel. Pakai rule of thumb jika tidak ada data yang bisa mendukung perhitungan jumlah sampel.\nEffect size tidak boleh mengutip dari penelitian lain secara eksplisit di proposal."
  },
  {
    "objectID": "metpen.html#effect-size-confident-interval-and-p-value",
    "href": "metpen.html#effect-size-confident-interval-and-p-value",
    "title": "38  Metodologi Penelitian",
    "section": "38.7 Effect Size, Confident Interval, and P Value",
    "text": "38.7 Effect Size, Confident Interval, and P Value"
  },
  {
    "objectID": "metpen.html#research-design",
    "href": "metpen.html#research-design",
    "title": "38  Metodologi Penelitian",
    "section": "38.7 Research Design",
    "text": "38.7 Research Design\nJenis penelitian digunakan untuk membuktikan tujuan penelitian.\nSebainya tidak perlu dilakukan analisis untuk mendapatkan nilai P untuk membandingkan karakteristik sampel antar 2 kelompok sebagai usaha untuk menunjukan 2 kelompok tersebut komparabel, jika kita tidak menghipotesiskan seperti itu.\nDesain:\n\n38.7.1 Cross sectional\nPengukuran variabel bebeas dan tergantung terjadi bersamaan. Baik untuk penyakit yang durasi sakitnya lama, dan kejadian cukup banyak.\n\n\n38.7.2 Kasus-Kontrol\nIdentifikasi sampel dengan variabel tergantung dulu, kemudian dicari kontrolnya, lalu dilihat secara retrospektif mencari variabel bebasnya. Lalu dihitung rasio odds. Odds: Perbandingan terjadinya efek dibandingkan tidak terjadinya efek pada suatu kelompok Rasio Odds: perbandingan odds antar 2 kelompok.\nMatching case control:\nVariabel bebas bisa banyak\n\n\n38.7.3 kohort\nMengidentifikasi variabel bebas, lalu diobersevari untuk melihat variabel tergantung. Baik untuk kasus yang jarang, dan perjalananya penyakit jarang.\nVariabel tergantung bisa banyak\n\n\n38.7.4 Nested Case-Cohort Study atau Nested Control Study\nUmumnya penelitian yang sampelnya bisa disimpan di Lab dan pemeriksaannya mahal. Controlnya: di matching => case cohort study Controlnya: di Random => case control study\n\n\n38.7.5 Uji Diagnostik\nSelalu tabel 2 x 2."
  },
  {
    "objectID": "metpen.html#cross-sectional-and-case-control",
    "href": "metpen.html#cross-sectional-and-case-control",
    "title": "38  Metodologi Penelitian",
    "section": "38.8 Cross Sectional and Case Control",
    "text": "38.8 Cross Sectional and Case Control"
  },
  {
    "objectID": "metpen.html#cohort-study",
    "href": "metpen.html#cohort-study",
    "title": "38  Metodologi Penelitian",
    "section": "38.9 Cohort Study",
    "text": "38.9 Cohort Study"
  },
  {
    "objectID": "metpen.html#experiments",
    "href": "metpen.html#experiments",
    "title": "38  Metodologi Penelitian",
    "section": "38.10 Experiments",
    "text": "38.10 Experiments"
  },
  {
    "objectID": "metpen.html#diagnostic-test",
    "href": "metpen.html#diagnostic-test",
    "title": "38  Metodologi Penelitian",
    "section": "38.11 Diagnostic Test",
    "text": "38.11 Diagnostic Test"
  },
  {
    "objectID": "metpen.html#data-management-and-analysis",
    "href": "metpen.html#data-management-and-analysis",
    "title": "38  Metodologi Penelitian",
    "section": "38.12 Data Management and Analysis",
    "text": "38.12 Data Management and Analysis"
  },
  {
    "objectID": "metpen.html#research-proposal",
    "href": "metpen.html#research-proposal",
    "title": "38  Metodologi Penelitian",
    "section": "38.13 Research Proposal",
    "text": "38.13 Research Proposal"
  },
  {
    "objectID": "metpen.html#ethical-issue",
    "href": "metpen.html#ethical-issue",
    "title": "38  Metodologi Penelitian",
    "section": "38.14 Ethical Issue",
    "text": "38.14 Ethical Issue"
  },
  {
    "objectID": "metpen.html#novelty-aspect",
    "href": "metpen.html#novelty-aspect",
    "title": "38  Metodologi Penelitian",
    "section": "38.15 Novelty Aspect",
    "text": "38.15 Novelty Aspect"
  },
  {
    "objectID": "filsum.html#pengantar-filsafat-ilmu",
    "href": "filsum.html#pengantar-filsafat-ilmu",
    "title": "39  Filsafat Ilmu",
    "section": "39.1 Pengantar Filsafat Ilmu",
    "text": "39.1 Pengantar Filsafat Ilmu\nFilsafat ilmu: untuk mencari tujuan hidup.\nOntology : study of existence, becoming and reality, mengetahui segala sesuatu yang ada sebagaimana adanya. Mencari tahu tentang hal terkait. Epistemology : Study of knowledge, bagaimana kita bisa mendapatkan pengetahuan yang hakiki itu atau sesuatu yang ada sebagai mana adanya. Mengetahui semua hal untuk mencapai sesuatu/how to achieve it.\nDeduktif: Mencari ke arah spesifik\nInduktif: Mencari teori (ke arah umum)\nAksiology : Study of Value, ilmu pengetahuan yang didapat itu bisa diterapkan untuk kemahaslatan umat atau justru sebaliknya. bagaimana cara menggunakan ilmunya\npengetahuan +> 5 panca indra, pengetahuan bisa menjadi ilmu jika melalui ilmiah dan dapat diturunkan/semua bisa mempelajari dengan hasil yang sama.\nFilsafat ilmu sebagai kumpulan teori digunakan memahami dan mereaksi dunia pemikiran."
  },
  {
    "objectID": "filsum.html#ilmu-sebagai-produk-berpikir",
    "href": "filsum.html#ilmu-sebagai-produk-berpikir",
    "title": "39  Filsafat Ilmu",
    "section": "39.2 Ilmu Sebagai Produk Berpikir",
    "text": "39.2 Ilmu Sebagai Produk Berpikir"
  },
  {
    "objectID": "filsum.html#ilmu-dan-teknologi-kedokteran",
    "href": "filsum.html#ilmu-dan-teknologi-kedokteran",
    "title": "39  Filsafat Ilmu",
    "section": "39.3 Ilmu dan Teknologi Kedokteran",
    "text": "39.3 Ilmu dan Teknologi Kedokteran"
  },
  {
    "objectID": "filsum.html#ontologi-epistemologi-dan-aksiologi-kedokteran",
    "href": "filsum.html#ontologi-epistemologi-dan-aksiologi-kedokteran",
    "title": "39  Filsafat Ilmu",
    "section": "39.4 Ontologi, Epistemologi, dan Aksiologi Kedokteran",
    "text": "39.4 Ontologi, Epistemologi, dan Aksiologi Kedokteran"
  },
  {
    "objectID": "filsum.html#intelektualitas-dan-aktivitas-intelektual",
    "href": "filsum.html#intelektualitas-dan-aktivitas-intelektual",
    "title": "39  Filsafat Ilmu",
    "section": "39.5 Intelektualitas dan Aktivitas Intelektual",
    "text": "39.5 Intelektualitas dan Aktivitas Intelektual"
  },
  {
    "objectID": "filsum.html#pengetahuan-dan-ilmu-pengetahuan",
    "href": "filsum.html#pengetahuan-dan-ilmu-pengetahuan",
    "title": "39  Filsafat Ilmu",
    "section": "39.6 Pengetahuan dan Ilmu Pengetahuan",
    "text": "39.6 Pengetahuan dan Ilmu Pengetahuan"
  },
  {
    "objectID": "filsum.html#teori-kebenaran-ilmiah",
    "href": "filsum.html#teori-kebenaran-ilmiah",
    "title": "39  Filsafat Ilmu",
    "section": "39.7 Teori Kebenaran Ilmiah",
    "text": "39.7 Teori Kebenaran Ilmiah"
  },
  {
    "objectID": "filsum.html#perkembangan-ilmu-kedokteran",
    "href": "filsum.html#perkembangan-ilmu-kedokteran",
    "title": "39  Filsafat Ilmu",
    "section": "39.8 Perkembangan Ilmu Kedokteran",
    "text": "39.8 Perkembangan Ilmu Kedokteran"
  },
  {
    "objectID": "filsum.html#aksiologi-sikap-ilmiah-dan-etika-ilmiah",
    "href": "filsum.html#aksiologi-sikap-ilmiah-dan-etika-ilmiah",
    "title": "39  Filsafat Ilmu",
    "section": "39.9 Aksiologi, Sikap Ilmiah dan Etika Ilmiah",
    "text": "39.9 Aksiologi, Sikap Ilmiah dan Etika Ilmiah"
  },
  {
    "objectID": "filsum.html#complementary-alternative-medicine",
    "href": "filsum.html#complementary-alternative-medicine",
    "title": "39  Filsafat Ilmu",
    "section": "39.10 Complementary & Alternative Medicine",
    "text": "39.10 Complementary & Alternative Medicine"
  },
  {
    "objectID": "filsum.html#komunikasi-ilmiah",
    "href": "filsum.html#komunikasi-ilmiah",
    "title": "39  Filsafat Ilmu",
    "section": "39.11 Komunikasi Ilmiah",
    "text": "39.11 Komunikasi Ilmiah"
  },
  {
    "objectID": "filsum.html#bioetika-penelitian",
    "href": "filsum.html#bioetika-penelitian",
    "title": "39  Filsafat Ilmu",
    "section": "39.12 Bioetika Penelitian",
    "text": "39.12 Bioetika Penelitian"
  },
  {
    "objectID": "filsum.html#publikasi-dan-hak-paten",
    "href": "filsum.html#publikasi-dan-hak-paten",
    "title": "39  Filsafat Ilmu",
    "section": "39.13 Publikasi dan Hak Paten",
    "text": "39.13 Publikasi dan Hak Paten"
  },
  {
    "objectID": "filsum.html#filsafat-ketuhatan-dan-kemanusiaan",
    "href": "filsum.html#filsafat-ketuhatan-dan-kemanusiaan",
    "title": "39  Filsafat Ilmu",
    "section": "39.14 Filsafat Ketuhatan dan Kemanusiaan",
    "text": "39.14 Filsafat Ketuhatan dan Kemanusiaan"
  },
  {
    "objectID": "filsum.html#metode-penalaran-ilmiah",
    "href": "filsum.html#metode-penalaran-ilmiah",
    "title": "39  Filsafat Ilmu",
    "section": "39.15 Metode Penalaran Ilmiah",
    "text": "39.15 Metode Penalaran Ilmiah"
  },
  {
    "objectID": "ebm.html#introduction-to-ebm-and-critical-appraisal",
    "href": "ebm.html#introduction-to-ebm-and-critical-appraisal",
    "title": "41  Evidence-based Medicine",
    "section": "41.1 Introduction to EBM and Critical Appraisal",
    "text": "41.1 Introduction to EBM and Critical Appraisal\nAdanya gap antara hasil penelitian dengan praktek sehari hari\nODDS Ratio: rasio terjadinya outcome pada kelompok dgn faktor risiko dengan tidak terjadinya outcome pada kelompok tersebut.\nHow EBM help: membantu informasi baru, memberikan data empiris dan patien bisa berpartisipasi dalam decision, reduce litigation, keep up to date.\nInterpretasi OR: < 1, misal 0,6 : risiko 60% kali dibandingkan kontrol, mengurangi risiko 40% (berapa dari 1) Interpretasi OR: > 1, misal 1,5 : risiko 150% atau 1,5 kali lebih besar pada klpk perlakuan, menambah risiko 50%\nHigh sensitivity, if negative, rule out (SnNout) High spesifisity, if positive, rule in (SpPin)\nSTeps in EBM\n\nFormulate an answerable question\nTrack down the best evidence of outcomes available\nCritically appraise the evidence\nApply the evidence\n\n3 prinsip EBM: 1. Valid\n2. Penting (penting secara klinis dan bermakna secara statistik: hasil, lihat PR, OR, RR,ARR, NNT, mean difference) 3. Aplikabel - Feasible? - kebutuhan lain yg dubutuhkan untuk memanfaatkan evidence? - Alternatif ada? - kemiripan sampel dan pasien kita? - benefit outweight risk? - Bagaiaman tanggapan pasien?\nf method untuk estimasi risiko pasien. NNT pada trial dibagi NNT pada pasien kita.\n\nEvaluate our performance\n\n\nevaluasi informal dan formal."
  },
  {
    "objectID": "ebm.html#clinical-question-berdasarkan-pico",
    "href": "ebm.html#clinical-question-berdasarkan-pico",
    "title": "41  Evidence-based Medicine",
    "section": "41.2 Clinical Question berdasarkan PICO",
    "text": "41.2 Clinical Question berdasarkan PICO\nmemecahkan masalah klinis dengan pendekatan…\n\n41.2.1 Step 1\nproses EBM dimulai dengan skenario klinis yang memerlukan jawaban terbaik berdasarkan bukti ilmiah yang terbaik. “mengubah suatu masalah klinis menjadi masalah reseaarch”\n\nBackground question: general knowledge (a question root & disorder and other aspect of health care.), dicari dari litrev\nForeground question: pertanyaan pengetahuan spesifik untuk menentukan pilihan terapi tau tindakan. Penting menggunakan PICO\n\nP: patient, population, problem I : intervensi, exposure C: control, comparator O: outcome, eficacy\nClinical problem = belum sistematis, clinical question= sesuai komponen PICO, dan answerable question.\nContoh: kejang pada pasien 15 tahun, dengan demam. pertanyaan klinis yang mungkin muncul: - apa penyebab demam? - penyebab kejang? - obat terbaik?\nlalu masing masing pertanyaan diubah menjadi komponen PICO. umpama, pada pasien anak, apakah pemeriksaan lumbal pungsi lebih baik dari pemeriksaan DL dalam diagnosis DL??\nCOntoh 2: anak, 8 tahun, dirawat di PICO dengan severe GBS dan menggunakan ventilator. Pengathuan dasar ada terapi prednison, plasma exchange and other. apakah IVIG therapy deliver outcome better than other therapy? => Clinical Problem.\nPICO: P: child with sever GBS I/C: prednisone, IVIG, atau plasma exchange O: cepat kesembuhan\ngood, clear and focused\n\n\n41.2.2 Prinsip Dasar Searching\nboelean logic: AND, OR, NOT\nTugas mencari permasalahan klinis, ubah menjadi pertanyaan research, lalu search dengan Boolean logic di Pubmed : https://wiryadana.github.io/picolo/"
  },
  {
    "objectID": "ebm.html#effect-size-hypothesis-and-confidence-interval",
    "href": "ebm.html#effect-size-hypothesis-and-confidence-interval",
    "title": "41  Evidence-based Medicine",
    "section": "41.3 Effect Size, Hypothesis, and Confidence Interval",
    "text": "41.3 Effect Size, Hypothesis, and Confidence Interval\nbesarnya efek: suatu perbedaan klinisdisbeut juga point estimate. Contoh: Rasio prevalens, risiko relative, rasio odds, beda rerata.\nada 4 kemungkinan, - secara statistik signifikan, secara klinis signifikan - secara statistik signifikan, secara klinis tidak signifikan - secara statistik tidak signifikan, secara klinis signifikan - secara statistik tidak signifikan, secara klinis tidak signifikan.\nSebagai klinisi kita mengutamakan clinically important dengan desain yang valid.\nHipotesis positif = adanya hubungan, perbedaan terkecil yang secara klinis yang dianggap penting. hipotesis negatif = tidak ada hubungan, perbedaan terbesar yang secara klinis tidak dianggap penting (non-inferiority)\nContoh: sebuah jurnal melaporkan ksesmbuhan obat A 80%, obat B 55%. Jika melakukan penelitian ulang, maka tidak dibenarkan menggunakan angka 25% sebagai effect size, ada 2 alasan.\n\nalasan konseptual, kenapa harus diulang jika sudah ada nilai 25%\nalasan teknis, jika efek size ternyata 23, maka bisa secara statistik tidak signifikan, padahal masih bermakna klinis.\n\nOleh sebab itu, penentuan efek size adalah judgement peneliti, tidak boleh dari penelitian orang lain.\nUntuk generalisasi atau inferensi ke populasi asal sampel diambil ada 2 cara, yaitu nilai P dan IK.\nVariabel adalah karakteristik subjek penelitian yang berubah antar subjek. Var perancu adalah variabel yang berhubungan dengan var bebas dan tergantung, tetapi bukan variabel perantara.\nTipe data: Data adalah hasil pengukuran. Pengukuran adalah proses kuantifikasi hasil observasi yang memperhatikan referensi tertentu dan dinyatakan dalam unit baku atau dianggap baku.\n\nskala kategorik\nskala numerik\n\nskala kategoril a. skala nominal (tidak ada derajat yang superior inferior) b. skala ordinal (ada derajat tapi tidak bisa dikuantifikasi secara matematika)\nSkala numerik a. skala interval: nilai nol tidak absolut (arbitrary) b. skaa ratio: nilai nol absolut\nlainnya Kontinyu: ada desimal diskreet: tidak ada desimal contoh jumlah keluarga.\nbebas vs tergantung (uji bivariat) Nominal vs nominal : chi kuadrat, uji fischer nominal (dikotom) vs numerik: uji T nominal (>2 nilai) vs numerik Anova Numerik vs numerik: korelasi/regresi\nJika tidak ada sebab akibat, pakai korelasi. Jika ada sebab (var bebas) dan akibat (tergangunt) pakai regresi\nMultivariat bebas vs tergantung numerik vs numerik : regresi multipel nominal, numerik vs nominal : regresi logistik\nData berpasangan: adalah data yang berasal dari orang/subjek yang sama atau subjek yang berbeda yang telah dilakukan matching. (ada before dan after)\nUji parametrik: a. koef varians: <30% b. uji K-S atau S-W\nUji homogenitas varians Uji levans\nUji non-parametrik\nInterpretasi nilai P: 0,035 besarnya kemungkinan untuk memperileh hasil tersebut disebabkan oleh faktor peluang bila H0 benar adalah sebesar 3,5%. Artinya 96,5% lainnya adalah akibat faktor obat.\nbila sampel kecil, nilai P bisa bermakna tetapi interval kepercayaan melewati nilai batas tidak signifikan."
  },
  {
    "objectID": "ebm.html#study-about-risk-factorcase-control-study",
    "href": "ebm.html#study-about-risk-factorcase-control-study",
    "title": "41  Evidence-based Medicine",
    "section": "41.4 Study About Risk Factor/Case Control Study",
    "text": "41.4 Study About Risk Factor/Case Control Study\nStart from dependent variable to independent variable. Harus jelas bagaiamna kita memilih kasus dan kontrolnya."
  },
  {
    "objectID": "ebm.html#study-about-diagnosis",
    "href": "ebm.html#study-about-diagnosis",
    "title": "41  Evidence-based Medicine",
    "section": "41.5 Study About Diagnosis",
    "text": "41.5 Study About Diagnosis\nEBM: integration of best research evidence with clinical expertise and patients values.\nSensitivitas dan spesifitias realtif stabil terhadap prevalensi penyakit PPV dan NPV harus memeprhatikan prevalensi penyakit di tempat kita."
  },
  {
    "objectID": "ebm.html#study-about-therapy",
    "href": "ebm.html#study-about-therapy",
    "title": "41  Evidence-based Medicine",
    "section": "41.6 Study about Therapy",
    "text": "41.6 Study about Therapy"
  },
  {
    "objectID": "ebm.html#study-about-prognosis",
    "href": "ebm.html#study-about-prognosis",
    "title": "41  Evidence-based Medicine",
    "section": "41.7 Study about Prognosis",
    "text": "41.7 Study about Prognosis"
  },
  {
    "objectID": "ebm.html#summary-capita-selekta",
    "href": "ebm.html#summary-capita-selekta",
    "title": "41  Evidence-based Medicine",
    "section": "41.8 Summary Capita Selekta",
    "text": "41.8 Summary Capita Selekta"
  },
  {
    "objectID": "tugasmkdu.html#biologi-molekuler",
    "href": "tugasmkdu.html#biologi-molekuler",
    "title": "42  Tugas MKDU",
    "section": "42.1 Biologi Molekuler",
    "text": "42.1 Biologi Molekuler"
  },
  {
    "objectID": "tugasmkdu.html#statistik",
    "href": "tugasmkdu.html#statistik",
    "title": "42  Tugas MKDU",
    "section": "42.2 Statistik",
    "text": "42.2 Statistik"
  },
  {
    "objectID": "tugasmkdu.html#metode-penelitian",
    "href": "tugasmkdu.html#metode-penelitian",
    "title": "42  Tugas MKDU",
    "section": "42.3 Metode Penelitian",
    "text": "42.3 Metode Penelitian\n\nTugas Metpen-1 - Association & Causation\n\nTugas/Pertanyaan/Instruksi\nMencari jurnal yang bisa menjadi acuan penelitian saat PPDS, jelaskan apakah jurnal tersebut association atau causation.\n\n\nJawaban/Hasil\nNama : Kadek Adit Wiryadana Prodi : Ilmu Penyakit Dalam Nim : 2371041012\n\nJudul Jurnal:\nImportance of Venous Congestion for Worsening of Renal Function in Advanced Decompensated Heart Failure\n\n\nTautan/Link:\nakses: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2856960/\n\n\nScreenshot:\n\n\n\nscreenshot Jurnal\n\n\n\n\nAlasan Association/causation:\nPenelitian Mullens et al diatas meneliti hubungan antara kongesti vena (CVP/central venous pressure) terhadap perburukan fungsi ginjal pada pasien dewasa dengan ADHF. Pertanyaan penelitian ini adalah apakah kongesti vena (diukur dengan kateter arteri pulmoner) merupakan faktor yang berasosiasi dengan perburukan fungsi ginjal pada pasien ADHF. Tujuan lainnya adalah menjawab apakah asosiasi tersebut lebih bermakna dibandingkan asosiasi penurunan cardiac output (diukur dengan cardiac index) terhadap penurunan fungsi ginjal, dimana secara umum teori yang diterima adalah faktor utama perburukan fungsi ginjal pada ADHF adalah penurunan cardiac output.\nPenelitian ini cenderung mendukung Causation antara kongesti vena dengan penurunan fungsi ginjal. Hal ini karena variabel independen berkontribusi terhadap penurunan fungsi ginjal (ditemukan asosiasi melalui perhitungan statistik). CVP ditemukan lebih tinggi baik saat admisi dan setelah mendapatkan terapi ADHF secara intensif pada pasien yang mengalami perburukan fungsi ginjal. Secara prospektif, ketika pasien mendapatkan terapi ADHF dan CVP berhasil diturunkan <8 mmHg, pasien yang kemudian mengalami perburukan fungsi ginjal lebih jarang ditemukan (mendukung prior association). Causation yang ditemukan merupakan contributory cause. Terdapat beberapa variabel yang bisa menjadi confounding karena tidak dilakukan pemeriksaan diantaranya regional renal perfusion, kelainan struktural ginjal, serta analisis data secara multivariabel tidak dilakukan\n\n\nIde Penelitian Selanjutnya:\nHubungan diameter dan collapsibility index inferior vena cava terhadap perburukan fungsi ginjal pada pasien acute decompensated heart failure."
  },
  {
    "objectID": "tugasmkdu.html#filsafat-ilmu-kedokteran",
    "href": "tugasmkdu.html#filsafat-ilmu-kedokteran",
    "title": "42  Tugas MKDU",
    "section": "42.4 Filsafat Ilmu Kedokteran",
    "text": "42.4 Filsafat Ilmu Kedokteran\n\nTugas Filsum-1 - Pengenalan filsafat ilmu\n\nTugas/Pertanyaan/Instruksi\nEpistemology\n\n\nJawaban/Hasil"
  },
  {
    "objectID": "tugasmkdu.html#evidence-based-medicine",
    "href": "tugasmkdu.html#evidence-based-medicine",
    "title": "42  Tugas MKDU",
    "section": "42.5 Evidence-based Medicine",
    "text": "42.5 Evidence-based Medicine\n\nTugas EBM-1 - Introduction to EBM & Critical Appraisal\n\nTugas/Pertanyaan/Instruksi\nInstruksi : Membuat pertanyaan klinis berdasarkan prinsip PICO !\nSkenario : Kita menghadapi anak dg defisiensi growth hormone (GH), apakah pemberian terapi GH eksogen dapat memacu pertumbuhan anak tersebut?\n\n\nJawaban/Hasil\n\nPICO\nP (patient/population) : Anak usia 2 - 14 tahun dengan isolated growth hormone deficiency (GH)\nI (intervention) : Terapi GH eksogen dengan dosis awal 25 mcg/kgBB/hari\nC (comparison/control): plasebo\nO (outcome) : laju peningkatan tinggi badan per tahun (\\(\\Delta\\) height velocity) >3 cm dalam 12 bulan terapi.\n\n\nPertanyaan Klinis\nPada pasien anak usia 2 -14 tahun dengan isolated growth hormone deficiency, apakah pemberian growth hormone eksogen sebagai terapi dapat meningkatkan \\(\\Delta\\) height velocity >3 cm/tahun pada 12 bulan terapi dibandingkan anak yang diberikan terapi plasebo.\n\n\nContekan\nhttps://academic.oup.com/jcem/article/93/2/352/2597982 https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2265.2012.04420.x https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6979443/"
  },
  {
    "objectID": "statistik.html#dasar-dasar-penulisan-ilmiah-kedokteran-dan-plagiarisme",
    "href": "statistik.html#dasar-dasar-penulisan-ilmiah-kedokteran-dan-plagiarisme",
    "title": "40  Statistik Kedokteran Dasar",
    "section": "40.1 Dasar-dasar Penulisan Ilmiah Kedokteran dan Plagiarisme",
    "text": "40.1 Dasar-dasar Penulisan Ilmiah Kedokteran dan Plagiarisme\nMetode sains: bisa diulang dengan hasil yang sama. observasi, measurement, verification and evaluation (self correction)\n\n40.1.1 Methods of acquiring knowledge\n\nMethod of Tenacity\nMethod of Authority\nMethod of Intuition\nMethod of Science\n\n\n\n40.1.2 Benefits of Conducting Research\n\nExpanding frontiers of knowledge\nNew inventions and discoveries\nSolving problems affecting the society\nIncreasing efficiency and reducing costs\nResearch strives to make life easier\nLuxury and comfort\nInfotainment\nEconomic growth\n\n\n\n40.1.3 Qualities of a researcher\n\nScientific attitude\nResearch aptitude\nPersistence\nSelf Motivation\nCourage to ask questions\nSkepticism and receptivity\nObjectivity\nIndustriousness\nHonesty and truthfulness\nOpen-mindedness\nAbove-average intelligence\nKnowledge\nImagination\nSelf-confidence\nSearch for perfection\nTeam spirit\n\n\n\n40.1.4 Bioethical\n\nAutonomy - consent to treatment\nBeneficence\nJustice\nUtility - balancing benefit\nInform Consent\nConfidentiality\n\n\n\n40.1.5 Induction and Deduction in Research\n\nDeductive reasoning is the process of reasoning from a general assumption to a specific application. Contoh: General proposition: all crows are black Specific proposition: this bird is a crow, therefore it is black\nIndcution normally involves generalization from the behavior of a few samples to that of a population contoh: all jasmine flowers are scented, if a situation or condition is true in all observed cases, then the situation or condition must be true in all cases.\nHypothetico-deductive method or inductive-deductive method.\n\n\n\n40.1.6 Scientific Method\nIt should be unprejudice\n\nMake observations or gather information\nDevelop hypothesis\nPredicts results\nDesign an experiment to falsify the hypothesis\nConduct the experiment and collect data\nEvaluation and conclusion\nAcceptance, modification or rejection of the hypothesis\n\n\n\n40.1.7 First Draft\n\nWhy did you start the experiment? (introduction)\nWhat did you do? How was it done (The materials and methods)\nWhat did you find? What was learned? (the results)\nWhat do the results mean? How do they relate to what is already known? (the discussion)\n\n\n\n40.1.8 Structure of a Research Paper\n\nTitle\nRunning Title\nAuthor\nInstitution\nAbstract\nKeywords\nIntroduction\nMaterials and Methods\nResults\nDiscussion\nConclusion\nAcknowledgements\nReferences\nTables and Figures\n\n\n\n40.1.9 Seven Categories of plagiarism\n\ndirect plagiarism\nmosaic plagiarism\nparaphrase plagiarism\ninsufficient acknowledgement\ncomplete plagiarism\nself plagiarism\naccidental plagiarism\n\n\n\n40.1.10 Characteristics of Good Research\n\nResearch is based on the work of others\nResearch is a blend of logic and imagination\nResearch tries to identify and avoid bias\nRepeatability\nResearch must be generalizable to other settings\nResearch is systematic\nResearch generates new questions\nResearch is an apolitical activity"
  },
  {
    "objectID": "statistik.html#korelasi-linier",
    "href": "statistik.html#korelasi-linier",
    "title": "40  Statistik Kedokteran Dasar",
    "section": "40.5 Korelasi Linier",
    "text": "40.5 Korelasi Linier\nDasar-dasar dan aplikasi biostatistika klinik\n\nmengestimasi kuatnya hubungan atau besarnya perbedaan (besarnya efek)\nmelakukan uji kemaknaan statistik (inferensial)\nmengontrol pengaruh variable pengganggu terhadap besar efek dan inferensi\n\nhubungan semu dapat diperoleh dari analissis bivariat, lalu multivariat untuk mengekslusi hubungan semu.\nKorelasi = antara independen dan dependennya memiliki hubungan garis lurus. Korelasi ada 2, liner dan non linier. Korelasi ada fleksibilitas variabel independen dan dependennya.\nJenis analisis statistik: - Tentukan pertama parametrik atau non-parametrik - Skala variabel: kontinyu (variabel skala dan interval), ordinal, nominal, diskriit - Uji normalitas: normal/non normal (tes kolmogorov smirnov atau shapiro-wilk) - Uji kesamaan varisi: sama/tidak sama (uji levene) - Uji kolinearitas: hubungan antar variabel independen (penting untuk uji partial korelasi, regresi linier berganda)\nvariabel: - jika bisa dipecah menjadi 5 atau lebih, bisa dikatakan continyu. - jika kontinyu dipecah menjadi beberapa kategori : bisa ordinal - jika yes no= nominal - diskrit = tidak bisa dibedakan antara kategori?\nPemilihan uji statistik: 1. tentukan variabel dependen (umumnya satu variable dependen) 2. tentukan jumlah variabel independen - bila tidak ada variabel independen, statistik yang dipakai adalah analisis univariat (deskriptif) - bila ada satu variabel independen, statistik yang dipakai adalah bivariat - bila ada lebih dari satu variable independen, statistik yang dipakai adalah analisis multivariat.\nSentral limit theorem: jika lebih dari 30 bisa berdistribusi normal."
  },
  {
    "objectID": "statistik.html#regresi-linier-sederhana",
    "href": "statistik.html#regresi-linier-sederhana",
    "title": "40  Statistik Kedokteran Dasar",
    "section": "40.6 Regresi Linier Sederhana",
    "text": "40.6 Regresi Linier Sederhana\n.. lanjutan korelasi linier dan regresi linier sederhana dan multipel\n\nMemilih analisis bivariat\n\n\n\n\n\n\n  \n    \n    \n      var_ind\n      var_dep\n      ana_biv\n      ana_mul\n    \n  \n  \n    kontinyu (normal)\nkontinyu(normal)\nkorelasi pearson(rho) ; regresi linier sederhana (slope, intercept)\nkorelasi pearson partial / regresi linier berganda\n    kontinyu(non-normal)\nkontinyu (non-normal)\nkorelasi speramn (rho)\nkorelasi spearman parsial\n  \n  \n  \n\n\n\n\n\nRegresi Linier\nasumsi regresi linier: - distribusi nornal - tidak ada kolinearity - variansi asusmsi sama\nRegresi nilai: intercept (a), slope/tangent (bx) dan error (e) Intercept: nilai Y saat X = O slope: perubahan rerata variabel dependen untuk setiap unit perubahan variabel independen\nYi = a + bX + ei (a atau b0 dan b1 adalah effect size) dan p value\n\n\nKorelasi Linier\nMengukur seberapa konsisten peribahan variabel indepen diikuti oleh peribahan variabel dependen (hubungan kovariansi) koefisien korelasi (r), menunjukan kekuatan hubungan antara variabel dependen dan variable independen.\nada 2 nilai: (rentang nilai -1 sd +1) - koefisien korelasi (rho), Ada kecenderungan hubungan x dengan y, tetapi tidak menunjukan seberapa kuat. - koefisien determinasi (r atau R2), seberapa persen pengaruh independen mempengaruhi dependen (effect size) - tambahan p value\ncontoh R2 adalah R2 45% pada konsumsi garam dan tekanan diastolik adalah variasi tekanan darah dapat dijelaskan sebesar 45% oleh konsuksi garam, sisanya 55% dijelaskan oleh factor lain. Nilai ini yang dimaknai oleh klinisi serta signifikansi korelasi (p) (kemungkinan hasil korelasi akibat by chance).\ntambah interpretasi regresi: a (intercept) = jika seorang tidak konsumsi garam berapa tekanan darahnya b (slope) = kenaikan tekanan darah setiap unit peningkatan konsumsi garam.\nPerbedaan korelasi dan regresi adalah korelasi belum bisa menentukan ind dan dependen, sedangkan regresi harus sudah ditentukan mana independen dan dependent.\nVisualisasi dengan scatter plot.\n\n\nRegresi dan korelasi Linier Berganda\nMultipel variabel independen melihat pengarihnya terhadap variabel dependen.\nJika menggunakan korelasi maka nilainya rho partial (korelasi partial), jika regresi multipel (regresi berganda) maka slopenya multipel (a + b0 + b1 + bx… + e)\nNisal: peneliti ingin mengetahui antara LFG (ml/menit) dengan estimasi data IMT (kg/m2), umur (tahun), dan TDD (mmhg), semua variabel independen berskala kontinyu.\nlfg = 72,74 + 3,11 (IMT) - 1,15 (umur) - 0,23 (tdd).\nR2 = 0,35, maka 3 variabel independen berperan 35% menjelaskan variabel dependen.\nUji hipotesis: hipotesis nol omnibus = kesalahan tipe 1 (\\(\\alpha\\)) merupakan hipotesis nol, artinya keseluruhan var indepen tidak dapat mengestimasi var dependen. Menguji B=0.\nKoefisien regresi (\\(\\beta\\)) pada persamaan regresi => hubungan antara variabel masing masing independen dan variabel dependen.\n\nAsas Kolinearitas\nPerhatikan nilai tolerance dan VIF (variance inflation factor). Nilai VIP besar lebih dari 10 atau tolerance < 0,10 maka dianggap terjadi multikolinearitas antara variabel dependen dalam model."
  },
  {
    "objectID": "statistik.html#korelasi-linier-dan-multipel",
    "href": "statistik.html#korelasi-linier-dan-multipel",
    "title": "40  Statistik Kedokteran Dasar",
    "section": "40.5 Korelasi Linier dan multipel",
    "text": "40.5 Korelasi Linier dan multipel\nDasar-dasar dan aplikasi biostatistika klinik\n\nmengestimasi kuatnya hubungan atau besarnya perbedaan (besarnya efek)\nmelakukan uji kemaknaan statistik (inferensial)\nmengontrol pengaruh variable pengganggu terhadap besar efek dan inferensi\n\nhubungan semu dapat diperoleh dari analissis bivariat, lalu multivariat untuk mengekslusi hubungan semu.\nKorelasi = antara independen dan dependennya memiliki hubungan garis lurus. Korelasi ada 2, liner dan non linier. Korelasi ada fleksibilitas variabel independen dan dependennya.\nJenis analisis statistik: - Tentukan pertama parametrik atau non-parametrik - Skala variabel: kontinyu (variabel skala dan interval), ordinal, nominal, diskriit - Uji normalitas: normal/non normal (tes kolmogorov smirnov atau shapiro-wilk) - Uji kesamaan varisi: sama/tidak sama (uji levene) - Uji kolinearitas: hubungan antar variabel independen (penting untuk uji partial korelasi, regresi linier berganda)\nvariabel: - jika bisa dipecah menjadi 5 atau lebih, bisa dikatakan continyu. - jika kontinyu dipecah menjadi beberapa kategori : bisa ordinal - jika yes no= nominal - diskrit = tidak bisa dibedakan antara kategori?\nPemilihan uji statistik: 1. tentukan variabel dependen (umumnya satu variable dependen) 2. tentukan jumlah variabel independen - bila tidak ada variabel independen, statistik yang dipakai adalah analisis univariat (deskriptif) - bila ada satu variabel independen, statistik yang dipakai adalah bivariat - bila ada lebih dari satu variable independen, statistik yang dipakai adalah analisis multivariat.\nSentral limit theorem: jika lebih dari 30 bisa berdistribusi normal."
  },
  {
    "objectID": "statistics.html#dataframe-operation",
    "href": "statistics.html#dataframe-operation",
    "title": "Statistics and R languange",
    "section": "Dataframe Operation",
    "text": "Dataframe Operation\n\n\n\nChecking the columns\n\n\n[1] \"Field.Name\"   \"Area\"         \"Slope\"        \"Vegetation\"   \"Soil.pH\"     \n[6] \"Damp\"         \"Worm.density\"\n\n\nSUmmary\n\n\n  Field.Name             Area           Slope        Vegetation       \n Length:20          Min.   :0.800   Min.   : 0.00   Length:20         \n Class :character   1st Qu.:2.175   1st Qu.: 0.75   Class :character  \n Mode  :character   Median :3.000   Median : 2.00   Mode  :character  \n                    Mean   :2.990   Mean   : 3.50                     \n                    3rd Qu.:3.725   3rd Qu.: 5.25                     \n                    Max.   :5.100   Max.   :11.00                     \n    Soil.pH         Damp          Worm.density \n Min.   :3.500   Mode :logical   Min.   :0.00  \n 1st Qu.:4.100   FALSE:14        1st Qu.:2.00  \n Median :4.600   TRUE :6         Median :4.00  \n Mean   :4.555                   Mean   :4.35  \n 3rd Qu.:5.000                   3rd Qu.:6.25  \n Max.   :5.700                   Max.   :9.00  \n\n\nThe use of aggregates function\n\n\n   Arable Grassland    Meadow   Orchard     Scrub \n 5.333333  2.444444  6.333333  9.000000  5.250000 \n\n\n\n\n  Community     Area    Slope  Soil.pH Worm.density\n1    Arable 3.866667 1.333333 4.833333     5.333333\n2 Grassland 2.911111 3.666667 4.100000     2.444444\n3    Meadow 3.466667 1.666667 4.933333     6.333333\n4   Orchard 1.900000 0.000000 5.700000     9.000000\n5     Scrub 2.425000 7.000000 4.800000     5.250000\n\n\nMultiple classification\n\n\n  moisture community     Area    Slope  Soil.pH Worm.density\n1    FALSE    Arable 3.866667 1.333333 4.833333     5.333333\n2    FALSE Grassland 3.087500 3.625000 3.987500     1.875000\n3     TRUE Grassland 1.500000 4.000000 5.000000     7.000000\n4     TRUE    Meadow 3.466667 1.666667 4.933333     6.333333\n5    FALSE   Orchard 1.900000 0.000000 5.700000     9.000000\n6    FALSE     Scrub 3.350000 5.000000 4.700000     7.000000\n7     TRUE     Scrub 1.500000 9.000000 4.900000     3.500000\n\n\n\nGet to Know the Data\n\nCheck if any unusual data points\n\n\n\n\n\nTo find which data is the outlier in the above scatter plot\n\n\n[1] 50\n\n\nSo it is the the 50 th data point.\n\n\nFind Relathionsip\n\nNumeric vs Numeric Variabales\n\n\n\n\n\nFrom plot above we can see : 1. The relathioship between response and explanatory variables is curved 2. Degree of scatter from left to right increases (non heterogenous), thus heterocedascity.\n\n\nCategorical vs Numeric Variabales\n\n\n\n\n\nWe see an overall pattern of temperature in a year. We see an outlier at month-6, it turns out a missing data that inputted as zero.\n\n\nmaking Conditional Plot (COPLOT)\n\n\n\nAlter graphics parameter to specifiy two sets of axis on the same row then make a simple scatter plot\n\n\n\n\n\nTo look for interaction between explanatory variables and response variables, we employ coplot. It plot Y agains X conditional on the value of Z. Z is numeric variables, by default the coplot split Z into six graphs, with the lowest value appear in the bottom left-hand.\n\n\n\n\n\nThe relathiosip of X and Y change according to Z, as increasing Z the trend comes positive.\n\n\nInteraction in Categorical Data\n\n\n\n\n\n\n\n\nFinding mean for each groups\n\n\n         no      yes\nno  1.47384 1.875928\nyes 2.28999 3.480184\n\n\n\n\n\n\n\nNitrogen only, gives (effect sizes) 2.29/1.47 (1.55) while nitrogen + phosporus gives 3,48/1.87 (1.86) increase in yield. Thus effect size of nitrogen increase depends on phosporus. This is called statistical interaction."
  },
  {
    "objectID": "metpen.html#hypothesis-and-hypothesis-testing-effect-size-confident-interval-and-p-value",
    "href": "metpen.html#hypothesis-and-hypothesis-testing-effect-size-confident-interval-and-p-value",
    "title": "38  Metodologi Penelitian",
    "section": "38.5 Hypothesis and Hypothesis Testing & Effect Size, Confident Interval, and P Value",
    "text": "38.5 Hypothesis and Hypothesis Testing & Effect Size, Confident Interval, and P Value\nHypothesis:\na statement about relathionsip between two or more variables that suggest an answer to the research question, is declarative statement that predicts an expected outcome.\nResearch hypothesis: kalimat deklaratif yang mencoba memberikan jawaban sementara atas pertanyaan penelitian.\nStatistical hypotesis: biasanya tidak ditulis di proposal.\nResearch hypothesis nanti akan di uji apakah hypotesis didukukng oleh data data.\nJika hypotesis yang kita uji tidak sesuai dengan data, maka bukan berarti ilmu itu salah"
  },
  {
    "objectID": "statistics.html#central-tendency",
    "href": "statistics.html#central-tendency",
    "title": "Statistics and R languange",
    "section": "Central Tendency",
    "text": "Central Tendency"
  },
  {
    "objectID": "statistics.html#variance",
    "href": "statistics.html#variance",
    "title": "Statistics and R languange",
    "section": "Variance",
    "text": "Variance\nA measure of variability is perhaps the most important quantity in statistical analysis. The greater variability ~ the greater the uncertainty, the harder to distinguish competing hypothesis.\n\nIlustration of Variance\nJust learn how to make the graph\nFinding Range\n\n\n\n\n\n[1]  5 15\n\n\n\n\nIllustration of Mean Value\n\n\n\n\n\nWhen Variance are different, dont compare the means."
  },
  {
    "objectID": "statistics.html#single-samples",
    "href": "statistics.html#single-samples",
    "title": "Statistics and R languange",
    "section": "Single-Samples",
    "text": "Single-Samples\n\nwhat is the mean value?\nis it different from current expectation or theory?\nwhat is the estimate?"
  },
  {
    "objectID": "statistics.html#two-samples",
    "href": "statistics.html#two-samples",
    "title": "Statistics and R languange",
    "section": "Two-Samples",
    "text": "Two-Samples"
  },
  {
    "objectID": "statistics.html#regression",
    "href": "statistics.html#regression",
    "title": "Statistics and R languange",
    "section": "Regression",
    "text": "Regression"
  },
  {
    "objectID": "statistics.html#analysis-of-variance",
    "href": "statistics.html#analysis-of-variance",
    "title": "Statistics and R languange",
    "section": "Analysis of Variance",
    "text": "Analysis of Variance"
  },
  {
    "objectID": "statistics.html#analysis-of-covariance-ancova",
    "href": "statistics.html#analysis-of-covariance-ancova",
    "title": "Statistics and R languange",
    "section": "Analysis of Covariance (ANCOVA)",
    "text": "Analysis of Covariance (ANCOVA)\nAncova involves a combination of regression and analysis of variance. The response variable is a continous, and there is at least one continous explanatory variable & at least one categorical variable.\nPrinciple of parsimony If the simpler model does not explain significantly less of the variation in the response, then the simpler model preferred. Test explanatory power: Anova or AIC\n\nanova: retain the more complicated model,\nAIC: prefer model with lower value.\n\nIllustration: response variable: fruit explanatory variable: root size and grazing\n\n\n[1] \"Root\"    \"Fruit\"   \"Grazing\"\n\n\n'data.frame':   40 obs. of  3 variables:\n $ Root   : num  6.22 6.49 4.92 5.13 5.42 ...\n $ Fruit  : num  59.8 61 14.7 19.3 34.2 ...\n $ Grazing: chr  \"Ungrazed\" \"Ungrazed\" \"Ungrazed\" \"Ungrazed\" ...\n\n\nFirst lets see the data\n\n\n\n\n\nBigger roots produced more seeds\n\n\n\n\n\n  Grazed Ungrazed \n 67.9405  50.8805 \n\n\nIt seems that the grazed plants produced more fruits. Lets do the ANOVA\n\n\n            Df Sum Sq Mean Sq F value Pr(>F)  \ncom$Grazing  1   2910  2910.4   5.309 0.0268 *\nResiduals   38  20833   548.2                 \n---\nSignif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1\n\n\nIt is indeed significant from ANOVA.\nLets do the ANCOVA, we use the most complex model, two intercept and two slopes for the grazed and ungrazed (use asterisk*). in ANCOVA, order of the explanatory variables matter.\nROOT first\n\n\n                     Df Sum Sq Mean Sq F value   Pr(>F)    \ncom$Root              1  16795   16795 359.968  < 2e-16 ***\ncom$Grazing           1   5264    5264 112.832 1.21e-12 ***\ncom$Root:com$Grazing  1      5       5   0.103     0.75    \nResiduals            36   1680      47                     \n---\nSignif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1\n\n\nGrazing first\n\n\n                     Df Sum Sq Mean Sq F value   Pr(>F)    \ncom$Grazing           1   2910    2910  62.380 2.26e-09 ***\ncom$Root              1  19149   19149 410.420  < 2e-16 ***\ncom$Grazing:com$Root  1      5       5   0.103     0.75    \nResiduals            36   1680      47                     \n---\nSignif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1\n\n\nBoth produces similar error sum of square (1680) and interaction sum of squares (5). The regression sum of square where higher when root fitted after grazing (19149) then before grazing (16795) due to non-orthogonal data.\nThe SSRdiff, representing differences in slope between grazed and ungrazed treatments appear insignificant, thus we can remove it. Then we fit difference intercepts for grazed and ungrazed plants but fit the same slope to both graphs (we use + sign in formula):\n\n\n            Df Sum Sq Mean Sq F value  Pr(>F)    \ncom$Grazing  1   2910    2910   63.93 1.4e-09 ***\ncom$Root     1  19149   19149  420.62 < 2e-16 ***\nResiduals   37   1684      46                    \n---\nSignif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1\n\n\nDoes the simpler model have significantly lower explanatory power? we use anova:\n\n\nAnalysis of Variance Table\n\nModel 1: com$Fruit ~ com$Grazing * com$Root\nModel 2: com$Fruit ~ com$Grazing + com$Root\n  Res.Df    RSS Df Sum of Sq      F Pr(>F)\n1     36 1679.7                           \n2     37 1684.5 -1   -4.8122 0.1031   0.75\n\n\nthe simpler model does not produce lower explanatory power (p = 0,75), thus we can adopt it.\nif we see the linear model of model2\n\n\n\nCall:\nlm(formula = com$Fruit ~ com$Grazing + com$Root)\n\nResiduals:\n     Min       1Q   Median       3Q      Max \n-17.1920  -2.8224   0.3223   3.9144  17.3290 \n\nCoefficients:\n                    Estimate Std. Error t value Pr(>|t|)    \n(Intercept)         -127.829      9.664  -13.23 1.35e-15 ***\ncom$GrazingUngrazed   36.103      3.357   10.75 6.11e-13 ***\ncom$Root              23.560      1.149   20.51  < 2e-16 ***\n---\nSignif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1\n\nResidual standard error: 6.747 on 37 degrees of freedom\nMultiple R-squared:  0.9291,    Adjusted R-squared:  0.9252 \nF-statistic: 242.3 on 2 and 37 DF,  p-value: < 2.2e-16\n\n\nThe model has high explanatory variables, accounting for 93% variation (multiple r squared). The intercept (-127.8) is the intercept for the graph of fruit production against plant rootstock size for the grazing variable which the factor level whose come first (in this case grazed).\n\n\n[1] \"Grazed\"   \"Ungrazed\"\n\n\nThe com\\(GrazingUngrazed is the difference in intercept for the ungrazed plants (-127.8 + 36.1 = -91.726). THe com\\)Root is the slope, the gradient of fruit production against initial rootstock size. It is same for both grazed or ungrazed, if it is difference it will showed in the fourth row the difference between slopes.\n\n\n\n\n\nThis showed that, the Grazed plants had relatively larger rootstock size then ungrazed plants, thus explain why in the boxplot of fruit ~ grazing showed that grazed plants produce more fruits while it actually reduce fruit production."
  },
  {
    "objectID": "statistics.html#multiple-regression",
    "href": "statistics.html#multiple-regression",
    "title": "Statistics and R languange",
    "section": "Multiple Regression",
    "text": "Multiple Regression"
  },
  {
    "objectID": "statistics.html#contrast",
    "href": "statistics.html#contrast",
    "title": "Statistics and R languange",
    "section": "Contrast",
    "text": "Contrast"
  },
  {
    "objectID": "statistics.html#other-response-variables",
    "href": "statistics.html#other-response-variables",
    "title": "Statistics and R languange",
    "section": "Other Response Variables",
    "text": "Other Response Variables"
  },
  {
    "objectID": "statistics.html#count-data",
    "href": "statistics.html#count-data",
    "title": "Statistics and R languange",
    "section": "Count Data",
    "text": "Count Data"
  },
  {
    "objectID": "statistics.html#proportion-data",
    "href": "statistics.html#proportion-data",
    "title": "Statistics and R languange",
    "section": "Proportion Data",
    "text": "Proportion Data"
  },
  {
    "objectID": "statistics.html#binary-response-variable",
    "href": "statistics.html#binary-response-variable",
    "title": "Statistics and R languange",
    "section": "Binary Response Variable",
    "text": "Binary Response Variable"
  },
  {
    "objectID": "statistics.html#death-and-failure",
    "href": "statistics.html#death-and-failure",
    "title": "Statistics and R languange",
    "section": "Death and Failure",
    "text": "Death and Failure"
  },
  {
    "objectID": "biomol.html#mutastion-free-radical-antioksidan",
    "href": "biomol.html#mutastion-free-radical-antioksidan",
    "title": "37  Biologi Molekular",
    "section": "37.6 Mutastion & Free Radical & Antioksidan",
    "text": "37.6 Mutastion & Free Radical & Antioksidan\nMutasi basa: substitusi, delesi, insensi.\n\n37.6.1 SUbstitusi biasanya terjadi 1 basa saja, sehingga sering juga disebut point mutation.\nSubstitusi bisa transversi menjadi transisi. Transisi: purin > purin Transversi: purin > pirimidin atau sebaliknya.\nHasil preotein: Silent mutation: asam amino sama Missense mutation: berubah kode asam amino Nonsense mutation: berubah menjadi stop kodon stop codon mutation: merubah stop kodon menjadi kodon asam amino.\n\n\n37.6.2 Delesi dan Insersi\nDelesi dan insersi mengubah reading frame, sehingga disebut dengan frameshift mutation.\n\n\n37.6.3 \n\n\n37.6.4 Molecular effect of Mutation\nWithin coding region - Silent (biasanya mutatasi pada basa ketiga di kodon, sering tidak mengganti asam amino) - Missense - Non-sense (premature stop codon) - Frameshift\nWithin non-coding region - SPlicing mutation - Regulatory Sequence mutation\n\n\n37.6.5 Clinical Effect of Mutation\n\nAcceptable\nPartially acceptable\nUnacceptable (fatal/letal)\n\nbisa menumbulkan kanker, inborn error metabolism.\nKanker muncul: - altered protein\n\n\n37.6.6 DNA Repair\n\nSPontaneous Mutation\n\nMismatch Repair DNA kita secara natural ada metilasi, jika belum termetilasi setelah replikasi maka akan di excisi oleh endonuclease.\n\n\n\nMetagen\n\nPhotoreactivation Timin Dimer, dipotong pada dimernya lalu dilakukan excision repair.\n\nTipe Repair - Base excision repor - Nucleotide excision repair.\n\n\n\n37.6.7 Free Radical\nMolekul yang memiliki elektron yang tidak berpasangan di orbit terluarnya. Radikal bebas tidak stabil, sehingga mencuri elektron dari molekul lain, dan mencipkan radikal bebas lain.\nOksidant: elektron acceptor, Fe3+ + e => Fe2+\nSifat: 1. Highly reactive, 2. Unstable 3. Very short half-life 4. Generate new radicals by chain reaction 5. Cause damage to biomolecules, cells\n\nReactive Oxygen Species (ROS)\n\nH2O2\n\nada juga Reactive nitrogen species\nSulit diperiksa secara langsung. Pemeriksaan secara tidak langsung dengan pemeriksaan produk dari hasil paparan radikal bebas.\nSumber radikal bebas: - Mitokondria pada proses pembentukan ATP,\n\n\nSumber Radikal Bebas\n\nEndogen\nEKsogen"
  },
  {
    "objectID": "biomol.html#dna-replication",
    "href": "biomol.html#dna-replication",
    "title": "37  Biologi Molekular",
    "section": "37.7 DNA Replication",
    "text": "37.7 DNA Replication\nReplikasi DNA terjadi pada fase S pada siklus sel bertujuan membuat copy DNA untuk diwarikan ke sel keturunanya."
  },
  {
    "objectID": "metpen.html#cross-sectional-case-control-study",
    "href": "metpen.html#cross-sectional-case-control-study",
    "title": "38  Metodologi Penelitian",
    "section": "38.8 Cross Sectional & Case-Control Study",
    "text": "38.8 Cross Sectional & Case-Control Study\n\n38.8.1 Cross-sectional Study\nCross sectional study assessing prevalence (old and new patient).\n\nFormulate appropriate research question and hypothesis\nIdentify indepent and dependent variables\nDetermine research subjects\nCarry out measurements\nDo analysis\n\nTabel 2x2 harus risk factor di kiri, effect di atas.\n\n\n\n38.8.2 Case-Control Study"
  },
  {
    "objectID": "anesthesiology.html#perioperative-consultation",
    "href": "anesthesiology.html#perioperative-consultation",
    "title": "17  Perioperative Consultation & Anesthesia",
    "section": "17.1 Perioperative Consultation",
    "text": "17.1 Perioperative Consultation\n\n17.1.1 Common Risk Score\n\nAssess Respiratory Risk in Surgical Patients in Catalonia (ARISCAT) Score\nIt used to predicts risk of pulmonary complications after surgery, including respiratory failure. Postoperative pulmonary complications (PPCs) include complications affecting the respiratory system after anesthesia and surgery. These complications are common, difficult to predict, and have significant effects on patient. The ARISCAT risk index is mostly used in operations other than thoracic surgery.\n\nApplicable to:\nPatients undergoing surgery under general, neuraxial, or regional anesthesia.\n\n\nScoring\n\n\nAdvice\nInterpretation:\nARISCAT Score\n\n\n\nRevised Lee Cardiac Risk Index for Pre-Operative Risk (RCRI)\nIt used to estimates risk of cardiac complications after non cardiac surgery. The RCRI score identifies a risk class based on the presence or absence of six factors (predictors) associated with preoperative cardiac complications.\n\nApplicable to:\n\nPatients ≥45 years old (or 18-44 years old with significant cardiovascular disease)\nUndergoing elective non-cardiac surgery or urgent/semi-urgent (non-emergent) non-cardiac surgery.\nUse with caution in emergency surgery patients, as the score is not as well validated in this population.\n\n\n\nScoring\nBaseline risk: 3,9% of 30-day risk of death, MI, or cardiac arrest Scoring Points Includes:\n\nElevated-risk surgery [YES / NO] Intraperitoneal; intrathoracic; suprainguinal vascular\nHistory of ischemic heart disease [YES / NO] History of myocardial infarction (MI); history of positive exercise test; current chest pain considered due to myocardial ischemia; use of nitrate therapy or ECG with pathological Q waves\nHistory of congestive heart failure [YES / NO] Pulmonary edema, bilateral rales or S3 gallop; paroxysmal nocturnal dyspnea; chest x-ray (CXR) showing pulmonary vascular redistribution\nHistory of cerebrovascular disease [YES / NO] Prior transient ischemic attack (TIA) or stroke\nPre-operative treatment with insulin [YES / NO] Pre-operative treatment with insulin\npre-operative creatinine [YES / NO] Pre-operative creatinine >2 mg/dL / 176.8 µmol/L\n\nSubsequently, it assigns a class (a risk index) from I-IV, listed below.\n\nClass I [0 predictores] correlates with a 3.9% 30-day risk of death, myocardial ischemia (MI), or cardiac arrest (CA).\nClass II [1 predictores] correlates with a 6% 30-day risk of death, MI, or CA.\nClass III [2 predictores] correlates with a 10.1% 30-day risk of death, MI, or CA.\nClass IV [greater than or equal to 3 predictors] correlates with a more than 15% 30-day risk of death, MI, or CA.\n\n\n\nAdvice\n\nIf the RCRI is ≥1, the patient’s age is ≥65, or they are between 45-64 with significant cardiac disease*, the next step is to measure the patient’s NT-ProBNP or BNP if this is available at your institution.\nIf the NT-ProBNP is ≥300 ng/L or BNP is ≥92 ng/L, then there should be an EKG ordered in the PACU and troponins should be measured daily for 48-72 hours.\nIf, after risk stratification, the NT-ProBNP is <300 ng/L or BNP <92 ng/L, no routine postoperative cardiac monitoring is warranted.\nIf the institution does not have these assays available, then all patients should be monitored with an EKG in the PACU and troponin measurements daily for 48-72 hours if they meet one of the following: RCRI ≥1, age ≥65, or age 45-64 with the aforementioned cardiac disease including:\n\nknown history of coronary artery disease,\ncerebral vascular disease,\nperipheral artery disease,\ncongestive heart failure,\nsevere PHTN or a severe obstructive intracardiac abnormality (e.g. severe aortic stenosis,\nsevere mitral stenosis, or severe hypertrophic obstructive cardiomyopathy).\n\n\n\n\n\nCAPRINI VTE Score\n\n\nIMPROVE Bleeding Score"
  },
  {
    "objectID": "anesthesiology.html#anesthesia",
    "href": "anesthesiology.html#anesthesia",
    "title": "17  Perioperative Consultation & Anesthesia",
    "section": "17.2 Anesthesia",
    "text": "17.2 Anesthesia\n\n17.2.1 Standard Anesthesia (just to know)\nPatients were monitored in the operating room under the ASA standards and 0.03 mg/kg midazolam was administered intravenously to the patients for premedication. Following preoxygenation; anesthesia was induced with 2–2.5 mg/kg propofol, 1–1.5 mcg/kg fentanyl, and 0.1 mg/kg vecuronium intravenously. After the intubation with a left-sided double-lumen endobronchial tube, anesthesia was maintained by administering 2–3% sevoflurane in oxygen and air mixture. Intraoperative lung-protective ventilation (tidal volume 5–7 mL/kg, positive end-expiratory pressure 5–7 cmH2O, and ventilatory plateau pressures below 30 cmH2O whenever possible) was administered in all patients.\n\n\n17.2.2 Standard Postoperative Analgesia Protocol\nBefore the end of the surgical procedure; metoclopramide, to prevent PONV; dexketoprofen (50 mg), and tramadol (100 mg) were given to the patients intravenously. Intravenous morphine was administered via patient-controlled analgesia (PCA) pump for 24 hours in the postoperative surgical intensive care unit. The PCA pump’s dose delivery was limited to administering a bolus dose of 1 mg morphine and delivering a maximum dose of 12 mg morphine in total within 4 hours with lockout intervals of 15 minutes. Paracetamol 1 g every 8 hours and dexketoprofen 50 mg twice daily were administered intravenously for multimodal analgesia. As a rescue analgesic agent, 0.5 mg/kg tramadol was given to patients intravenously when a score of VAS at coughing ≥ 4.\nhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9333546/"
  },
  {
    "objectID": "infectious_disease.html#bacterial-infection",
    "href": "infectious_disease.html#bacterial-infection",
    "title": "6  Infectious Disease",
    "section": "6.1 Bacterial Infection",
    "text": "6.1 Bacterial Infection"
  },
  {
    "objectID": "infectious_disease.html#viral-infection",
    "href": "infectious_disease.html#viral-infection",
    "title": "6  Infectious Disease",
    "section": "6.2 Viral Infection",
    "text": "6.2 Viral Infection\n\n6.2.1 HIV\n\nImunopatogenesis HIV Infection\n\n\n\n\n\n\n6.2.2 Dengue"
  },
  {
    "objectID": "infectious_disease.html#fungal-infection",
    "href": "infectious_disease.html#fungal-infection",
    "title": "6  Infectious Disease",
    "section": "6.3 Fungal Infection",
    "text": "6.3 Fungal Infection"
  }
]